

Poster #	Submitter's Last Name	Submitter's First Name	Title	Assigned Pathway	Poster Discussion Session	Concurrent Session
423	Abbruzzese	Jim	Expression Profiling Reveals That Epithelial-to-Mesenchymal Transition (EMT) Controls Global Drug Resistance in Pancreatic Cancer	Agents	Therapeutic Targeting in Pancreatic & Breast Cancer	Group III: 3:00-5:30pm
355	Abrams	Judith	Development of an Autoantibody-based Early Detection Test of Ovarian Cancer using Protein Microarrays	IRMs	Cellular Therapy for Immune Response Modification	Group II: 11:00-2:30pm
222	Aguilar-Cordova	Estuardo	Gene Mediated Cytotoxic Immunotherapy for Newly Diagnosed Prostate Cancer	Agents	New Agents for the Treatment & Prevention of Prostate Cancer	Group II: 11:00-2:30pm
366	Ahles	Tim	Genetics of Cognitive Decline Post Cancer Chemotherapy	Lifestyle	Biobehavioral Mechanisms in Cancer Progression & Control	Group II: 11:00-2:30pm
353	Albelda	Steven	Immuno- and Immuno-Gene Therapies for Thoracic Malignancies (Mesothelioma and Metastatic Pleural Disease) (PO1 CA066726)	IRMs	Cellular Therapy for Immune Response Modification	Group II: 11:00-2:30pm
472	Alonso	Sergio	Aging, DNA Hypomethylation, Genetic Alterations, and Gastrointestinal Cancer.	Biospecimens	Biomarkers: Esophagus, Colon, and Liver Cancers	Group III: 3:00-5:30pm
389	Altieri	Dario	Molecular Targeting of Mitochondrial Hsp90 Chaperones for Novel Cancer Therapeutics	Agents	Novel Targets in Hematological Malignancies	Group III: 3:00-5:30pm
153	Ambs	Stefan	Tumor Immunobiological Differences in Prostate Cancer between African-American and European-American Patients	IRMs	Antibodies, Cytokines, & Viruses	Group I: 8:00-10:30am
367	Ancoli-Israel	Sonia	The Relationship Between Sleep, Fatigue And Chemobrain In Women With Breast Cancer	Lifestyle	Biobehavioral Mechanisms in Cancer Progression & Control	Group II: 11:00-2:30pm
368	Andersen	Barbara	Psychological Intervention for Women with Breast Cancer	Lifestyle	Biobehavioral Mechanisms in Cancer Progression & Control	Group II: 11:00-2:30pm
79	Anderson	Karen	Using Custom Protein Microarrays to Identify Autoantibody Biomarkers for the Early Detection of Cancer	Biospecimens	-Omic Technology in Biomarker Discovery & Development	Group I: 8:00-10:30am
383	Anderson	Kenneth	Oncogenomics to Target the Myeloma Cell in its Bone Marrow Microenvironment	Agents	Novel Targets in Hematological Malignancies	Group III: 3:00-5:30pm
249	Anderson	Marshall	Strategy for Chemoprevention of Lung Cancer with Polyphenon E in a subset of Current and non-smokers	Agents	Targeting Head, Neck & Lung Cancers	Group II: 11:00-2:30pm
518	Andjelic	Sofijia	PSMA-VRP Vaccine for Prostate Cancer	IRMs	Cancer Vaccines	Group III: 3:00-5:30pm
384	Andreeff	Michael	Strategies for Overcoming Apoptosis and Microenvironment-Mediated Resistance in Acute Myelogenous Leukemia	Agents	Novel Targets in Hematological Malignancies	Group III: 3:00-5:30pm
156	Ang	Kian	Targeting Epidermal Growth Factor Receptor Signaling to Selectively Enhance Tumor Response to Radiation	Devices	Ionizing and Non-Ionizing Radiation	Group I: 8:00-10:30am
369	Antoni	Mike	Center For Psycho-Oncology Research: A Mind Body Center	Lifestyle	Biobehavioral Mechanisms in Cancer Progression & Control	Group II: 11:00-2:30pm
519	Antonia	Scott	Efficacy of Salvage Chemotherapy for Small Cell Lung Cancer is Enhanced with a p53- TargetingTumor Vaccine	IRMs	Cancer Vaccines	Group III: 3:00-5:30pm
242	Argiris	Athanasios	Cetuximab and bevacizumab in patients with recurre	Agents	Targeting Head, Neck & Lung Cancers	Group II: 11:00-2:30pm
176	Aronson	William	Growth Inhibitory Effect of a Low-Fat Diet on Prostate Cancer Cells in Vitro: Results of a Prospective Randomized Dietary Intervention Trial in Men with Prostate Cancer	Lifestyle	Dietary Components in Cancer Prevention & Control	Group I: 8:00-10:30am
520	Arredouani	Simo	Targeting Novel Prostate Tumor Antigens for Cancer Immunotherapy	IRMs	Cancer Vaccines	Group III: 3:00-5:30pm
431	Arteaga	Carlos	Loss of PTEN engages ErbB3 and IGF-I receptor signaling to promote antiestrogen resistance in breast cancer	Agents	Therapeutic Targeting in Pancreatic & Breast Cancer	Group III: 3:00-5:30pm
332	Atkins	Michael	Response of renal cell cancer mouse model to antiangiogenic therapy correlates with tumor perfusion as measured with arterial spin labeling MRI	Imaging	Imaging and Cancer Therapeutics	Group II: 11:00-2:30pm
480	Augenlich	Len	Diet, Inflammation and Tumor Formation in the Intestine	Biospecimens	Biomarkers: Esophagus, Colon, and Liver Cancers	Group III: 3:00-5:30pm
184	Augenlicht	Len	Diet, Inflammation and Tumor Formation in the Intestine	Lifestyle	Dietary Components in Cancer Prevention & Control	Group I: 8:00-10:30am
521	Avigan	David	Vaccination of Patients with Metastatic Renal Carcinoma with Dendritic Cell/Tumor Fusions Following Debulking Nephrectomy	IRMs	Cancer Vaccines	Group III: 3:00-5:30pm
102	Ayala	Gustavo	Tumor Microenvironment Based Prediction in Prostate Cancer	Biospecimens	Biomarkers for Prostate & Bladder Cancers	Group I: 8:00-10:30am
243	Backer	Joseph	Imaging VEGF Receptors in Tumor Angiogenesis with Novel scVEGF-based SPECT, PET, and NIRF Tracers	Agents	Targeting Head, Neck & Lung Cancers	Group II: 11:00-2:30pm
174	Baker	K. Scott	METABOLIC SYNDROME FOLLOWING TRANSPLANT FOR LEUKEMI/	Lifestyle	Dietary Components in Cancer Prevention & Control	Group I: 8:00-10:30am
175	Baker	K. Scott	Metabolic Syndrome in Childhood Cancer Survivors	Lifestyle	Dietary Components in Cancer Prevention & Control	Group I: 8:00-10:30am
19	Baker	Laurence	Treating Advanced Cancer by Disrupting the Tumor Ecosystem.	Agents	Biochemical Targets & Drug Screening	Group I: 8:00-10:30am
58	Baker	Suzanne	Normal and Neoplastic Growth in the Brain	Biospecimens	Biomarkers for Hematologic Malignancies & Pediatric Cancer	Group I: 8:00-10:30am
177	Barnes	Steve	PUBERTY AND POLYPHENOL-CONTAINING DIETS AND THE RISK OF BREAST CANCER	Lifestyle	Dietary Components in Cancer Prevention & Control	Group I: 8:00-10:30am
59	Barr	Frederic	The role of amplification in predicting clinical outcome of patients with alveolar rhabdomyosarcoma	Biospecimens	Biomarkers for Hematologic Malignancies & Pediatric Cancer	Group I: 8:00-10:30am
292	Bast	Robert	Optimizing a Two-Stage Strategy for Early Detection of Ovarian Cancer	Biospecimens	Prognostic & Predictive Biomarkers	Group II: 11:00-2:30pm
231	Basu	Hirak	Development of Penthamethylchromanol for Prostate Cancer Prevention	Agents	New Agents for the Treatment & Prevention of Prostate Cancer	Group II: 11:00-2:30pm
293	Batra	Surinder	Detection of MUC4 mRNA in Human Peripheral Blood Mononuclear Cells: Prognostic and Diagnostic Marker for Patients with Pancreatic Cancer	Biospecimens	Prognostic & Predictive Biomarkers	Group II: 11:00-2:30pm
482	Beer	David	Identification and Characterization of Amplified Gene Targets in Esophageal Adenocarcinoma	Biospecimens	Biomarkers: Esophagus, Colon, and Liver Cancers	Group III: 3:00-5:30pm
498	Belinsky	Steven	Gene Promoter Methylation in Lung Cancer: Identification of Genetic Determinants and Use in Disease Monitoring	Biospecimens	Biomarkers for Lung Cancer Detection & Therapy	Group III: 3:00-5:30pm
499	Bepler	Gerold	RRM1/PTEN Axis in Response and Survival of Non-Small Cell Lung Cancer	Biospecimens	Biomarkers for Lung Cancer Detection & Therapy	Group III: 3:00-5:30pm
178	Berger	Nathan	Behavioral Modulation of Genetic Predisposition to Hepatocellular Cancer	Lifestyle	Dietary Components in Cancer Prevention & Control	Group I: 8:00-10:30am
396	Beutler	John	Development of HTS Assays for Inhibitors of ERAD and the Ubiquitin Ligase gp78	Agents	Novel Targets in Hematological Malignancies	Group III: 3:00-5:30pm

Poster #	Submitter's Last Name	Submitter's First Name	Title	Assigned Pathway	Poster Discussion Session	Concurrent Session
320	Bhujwalla	Zaver	Molecular and Functional Imaging of Cancer	Imaging	Imaging and Cancer Therapeutics	Group II: 11:00-2:30pm
398	Bhujwalla	Zaver	Molecular and Functional Imaging of Cancer	Agents	Integrative Biology: Bench to Bedside	Group III: 3:00-5:30pm
60	Biegel	Jackie	Genomic Analysis Using High Density SNP-Based Oligonucleotide Arrays, Sequencing and MLPA Provides a Comprehensive Analysis of INI1/SMARCB1 in Malignant Rhabdoid Tumors	Biospecimens	Biomarkers for Hematologic Malignancies & Pediatric Cancer	Group I: 8:00-10:30am
481	Bigbee	Bill	Blood-based Detection of Colon Cancer Utilizing Specific Nuclear Matrix Proteins	Biospecimens	Biomarkers: Esophagus, Colon, and Liver Cancers	Group III: 3:00-5:30pm
434	Billadeau	Daniel	Regulation of Pancreatic Tumor Cell Proliferation and Chemoresistance by the Histone Methyltransferase EZH2	Agents	Therapeutic Targeting in Pancreatic & Breast Cancer	Group III: 3:00-5:30pm
298	Birrer	Michael	GOG #210: A Molecular Staging Study of Endometrial Cancer ζ A Cooperative Group-Initiated Resource to Facilitate Translational Research	Biospecimens	Prognostic & Predictive Biomarkers	Group II: 11:00-2:30pm
334	Bishop	Michael	Enhancement of Graft-Versus-Tumor (GVT) Effect to Prevent and Treat Relapse after Allogeneic Hematopoietic Cell Transplantation	IRMs	Cellular Therapy for Immune Response Modification	Group II: 11:00-2:30pm
421	Biswas	Swati	Monoclonal Antibody to Transforming Growth Factor beta Inhibits Cancer Progression in Multiple Preclinical Cancer Models	Agents	Therapeutic Targeting in Pancreatic & Breast Cancer	Group III: 3:00-5:30pm
370	Bloom	Joan	Exercise for Health: Young Breast Cancer Survivors	Lifestyle	Biobehavioral Mechanisms in Cancer Progression & Control	Group II: 11:00-2:30pm
335	Bollard	Catherine	ADMINISTRATION OF AUTOLOGOUS CYTOTOXIC T LYMPHOCYTES TARGETTING EBV LATENT MEMBRANE PROTEINS FOR THE TREATMENT OF LYMPHOMA	IRMs	Cellular Therapy for Immune Response Modification	Group II: 11:00-2:30pm
445	Brenner	Dean	Development and Application of Biosample Reference Sets for Preliminary Clinical Characterization of Biomarker for the Early Detection of Colorectal Adenocarcinoma.	Biospecimens	Biomarkers for Early Detection	Group III: 3:00-5:30pm
417	Broaddus	Russell	A phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, RAD001 (everolimus), in patients with recurrent endometrial carcinoma	Agents	Integrative Biology: Bench to Bedside	Group III: 3:00-5:30pm
158	Brock	Kristy	Dynamic Multi-Organ Models to Improve Radiotherapy Treatment of the Liver	Devices	Ionizing and Non-Ionizing Radiation	Group I: 8:00-10:30am
294	Brock	Malcolm	Using Epigenetic Biomarkers as Prognostic and Predictive Markers in Non-Small Cell Lung Cancer (NSCLC)	Biospecimens	Prognostic & Predictive Biomarkers	Group II: 11:00-2:30pm
399	Brown	Powel	Translational Cancer Prevention Studies: Testing Novel Agents for the Prevention of Estrogen Receptor-negative Breast Cancer	Agents	Integrative Biology: Bench to Bedside	Group III: 3:00-5:30pm
305	Bruce	Richard	Sensitive location and characterization of circulating tumor cells for improving therapy selection and monitoring treatment efficacy	Biospecimens	Prognostic & Predictive Biomarkers	Group II: 11:00-2:30pm
422	Buchsbaum	Don	Combined Modality Targeted Therapy of Pancreatic Cancer with Death Receptor Monoclonal Antibodies	Agents	Therapeutic Targeting in Pancreatic & Breast Cancer	Group III: 3:00-5:30pm
468	Buckner	Jan	Centralized Biorepositories for Cooperative Group Clinical Trials: The North Central Cancer Treatment Group (NCCTG) Approach	Biospecimens	Biomarkers for Early Detection	Group III: 3:00-5:30pm
302	Bueno	Raphael	A Four Gene Expression Ratio Test Prospectively Predicts Survival in Patients Undergoing Surgery for Mesothelioma	Biospecimens	Prognostic & Predictive Biomarkers	Group II: 11:00-2:30pm
82	Burns	Kathleen	Comprehensive transposon mapping in the human genome.	Biospecimens	-Omic Technology in Biomarker Discovery & Development	Group I: 8:00-10:30am
159	Busch	Theresa	Tumor Microenvironment and Vasoresponse during Photodynamic Therapy as Determinants of Therapeutic Outcome	Devices	Ionizing and Non-Ionizing Radiation	Group I: 8:00-10:30am
523	Butterfield	Lisa	A Phase I/II Trial Testing Immunization with AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients with Hepatocellular Carcinoma	IRMs	Cancer Vaccines	Group III: 3:00-5:30pm
139	Byrd	John	Targeting the Innate Immune System to Enhance Cancer Therapy	IRMs	Antibodies, Cytokines, & Viruses	Group I: 8:00-10:30am
2	Cagan	Ross	A Drosophila approach to exploring cancer mechanis	Agents	Biochemical Targets & Drug Screening	Group I: 8:00-10:30am
446	Cairns	Paul	Detection of Kidney and Bladder Cancer Gene Methylation in Urine DNA	Biospecimens	Biomarkers for Early Detection	Group III: 3:00-5:30pm
447	Califano	Joseph	Detection of promoter hypermethylation in saliva as a biomarker for head and neck squamous cell carcinoma surveillance	Biospecimens	Biomarkers for Early Detection	Group III: 3:00-5:30pm
224	Cantley, Jr.	Lewis	The Role of the PI3K/PTEN Signaling Network in Prostate Cancer.	Agents	New Agents for the Treatment & Prevention of Prostate Cancer	Group II: 11:00-2:30pm
321	Capala	Jacek	Molecular Targeting of HER2 for Diagnosis and Therapy of Breast Cancer	Imaging	Imaging and Cancer Therapeutics	Group II: 11:00-2:30pm
400	Capala	Jacek	Molecular Targeting of HER2 for Diagnosis and Therapy of Breast Cancer	Agents	Integrative Biology: Bench to Bedside	Group III: 3:00-5:30pm
33	Caplen	Natasha	RNAi analysis and screening for the study of cancer gene function and anti-cancer therapeutics.	Agents	Cancer Stem Cell, Gene Expression, & Epigenetic Targets	Group I: 8:00-10:30am
500	Carbone	David	Strategic Partnering to Evaluate Cancer Signatures in Lung Cancer	Biospecimens	Biomarkers for Lung Cancer Detection & Therapy	Group III: 3:00-5:30pm
505	Carbone	David	Shotgun proteomic analysis of non-small cell lung cancer tissue	Biospecimens	Biomarkers for Lung Cancer Detection & Therapy	Group III: 3:00-5:30pm
401	Carducci	Michael	Translation of Novel Agents in Early Phase Clinical Trials	Agents	Integrative Biology: Bench to Bedside	Group III: 3:00-5:30pm
83	Carr	Steven	Measuring Cancer Biomarker Candidates by Targeted MS and Ab Enrichment	Biospecimens	-Omic Technology in Biomarker Discovery & Development	Group I: 8:00-10:30am
95	Carr	Steven	PEPPeR: A High-Throughput Platform for Pattern-Based Biomarker Discovery using Fractionated Samples	Biospecimens	-Omic Technology in Biomarker Discovery & Development	Group I: 8:00-10:30am
103	Carrol	Peter	Molecular Effects of Nutritional Supplements on the Prostate Microenvironment	Biospecimens	Biomarkers for Prostate & Bladder Cancers	Group I: 8:00-10:30am
225	Carrol	Peter	Molecular Effects of Nutritional Supplements on the Prostate Microenvironment	Agents	New Agents for the Treatment & Prevention of Prostate Cancer	Group II: 11:00-2:30pm

Poster #	Submitter's Last Name	Submitter's First Name	Title	Assigned Pathway	Poster Discussion Session	Concurrent Session
145	Carson	William	Preclinical studies and clinical experience with the combination of interleukin-12 with trastuzumab and Paclitaxel in HER2-overexpressing malignancies	IRMs	Antibodies, Cytokines, & Viruses	Group I: 8:00-10:30am
524	Celis	Esteban	Focal Adhesion Kinase as an Immunotherapeutic Target for Prostate Cancer	IRMs	Cancer Vaccines	Group III: 3:00-5:30pm
297	Chaganti	Raju	Level of hypoxia-inducible factors HIF1α and HIF2α in tumors predicts response to sunitinib in renal cell carcinoma patients	Biospecimens	Prognostic & Predictive Biomarkers	Group II: 11:00-2:30pm
337	Champlin	Richard	Therapy of CML	IRMs	Cellular Therapy for Immune Response Modification	Group II: 11:00-2:30pm
84	Chan	Daniel	Translation of Proteomic Biomarker Discovery into Clinical Practice for the Early Detection of Cancer	Biospecimens	-Omic Technology in Biomarker Discovery & Development	Group I: 8:00-10:30am
62	Chan	Wing	Molecular diagnosis and target directed therapy in non-Hodgkin Lymphoma	Biospecimens	Biomarkers for Hematologic Malignancies & Pediatric Cancer	Group I: 8:00-10:30am
268	Chang	Jenny	Gene signature of cancer stem cells is...	Biospecimens	Biomarkers for Breast Cancer	Group II: 11:00-2:30pm
88	Chang	Jenny	Gene signature of cancer stem cells is...	Biospecimens	-Omic Technology in Biomarker Discovery & Development	Group I: 8:00-10:30am
338	Chao	Nelson	Engineering Optimal Hematopoietic Stem Cell Grafts	IRMs	Cellular Therapy for Immune Response Modification	Group II: 11:00-2:30pm
473	Chapkin	Robert	Non-invasive detection of candidate molecular biomarkers in patients at high risk for colorectal adenoma recurrence	Biospecimens	Biomarkers: Esophagus, Colon, and Liver Cancers	Group III: 3:00-5:30pm
30	Chen	Ching-Shih	Potent Indole-3-Carbinol-Derived Antitumor Agent with Pleiotropic Effects on Multiple Signaling Pathways	Agents	Biochemical Targets & Drug Screening	Group I: 8:00-10:30am
450	Chen	Ru	Pancreatic Cancer Protein Biomarkers for Early Detection	Biospecimens	Biomarkers for Early Detection	Group III: 3:00-5:30pm
56	Chen	Wei	Targeting Developmental Signaling Pathways, Such As Hedgehog/Smoothened, In Cancer	Agents	Cancer Stem Cell, Gene Expression, & Epigenetic Targets	Group I: 8:00-10:30am
104	Cheng	Leo	Prostate Cancer Metabolomics	Biospecimens	Biomarkers for Prostate & Bladder Cancers	Group I: 8:00-10:30am
167	Cherukuri	Murali Krishna	In Vivo Imaging of Tumor Oxygen Levels and Glycolytic Activity using Paramagnetic Resonance Imaging	Devices	Ionizing and Non-Ionizing Radiation	Group I: 8:00-10:30am
34	Cheung	Nai-Kong	Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma	Agents	Cancer Stem Cell, Gene Expression, & Epigenetic Targets	Group I: 8:00-10:30am
451	Chia	David	A Progress Report for a Biomarker Reference Laboratory (BRL) for Early Detection Research Network (EDRN)	Biospecimens	Biomarkers for Early Detection	Group III: 3:00-5:30pm
106	Chinnaiyan	Arul	A Fluorescence In situ Hybridization Screen for E26 Transformation ζ Specific Aberrations: Identification of DDX5-ETV4 Fusion Protein in Prostate Cancer	Biospecimens	Biomarkers for Prostate & Bladder Cancers	Group I: 8:00-10:30am
108	Chinnaiyan	Arul	A First Generation Multiplex Biomarker Analysis of Urine for the Early Detection of Prostate Cancer	Biospecimens	Biomarkers for Prostate & Bladder Cancers	Group I: 8:00-10:30am
226	Chow	Sherry	Early Phase Clinical Development of Polyphenon E for Cancer Prevention	Agents	New Agents for the Treatment & Prevention of Prostate Cancer	Group II: 11:00-2:30pm
35	Civin	Curt	Understanding and Targeting Cancer Stem Cells	Agents	Cancer Stem Cell, Gene Expression, & Epigenetic Targets	Group I: 8:00-10:30am
86	Clarke	Robert	Molecular Profiling of Human Breast Cancer	Biospecimens	-Omic Technology in Biomarker Discovery & Development	Group I: 8:00-10:30am
36	Clarkson	Baynard	The Quiescent Cancer Stem Cell and Defective Quorum Sensing: Major Obstacles to Curative Treatment of Cancer	Agents	Cancer Stem Cell, Gene Expression, & Epigenetic Targets	Group I: 8:00-10:30am
265	Clawson	Gary	Development of an RNA Sensor Platform for Detection of Circulating Tumor Cells	Biospecimens	Biomarkers for Breast Cancer	Group II: 11:00-2:30pm
452	Clawson	Gary	Development of an RNA Sensor Platform for Detection of Circulating Tumor Cells	Biospecimens	Biomarkers for Early Detection	Group III: 3:00-5:30pm
525	Clay	Tim	Vaccine Induced Antibodies Modulate Receptor Biology and Kill Tumors	IRMs	Cancer Vaccines	Group III: 3:00-5:30pm
46	Coffey	Robert	A novel, high-throughput biochemical screen of canonical Wnt signaling identifies a potent and specific inhibitor	Agents	Cancer Stem Cell, Gene Expression, & Epigenetic Targets	Group I: 8:00-10:30am
328	Coffey	Robert	Molecular imaging of therapeutic response to EGF receptor blockade in colorectal cancer	Imaging	Imaging and Cancer Therapeutics	Group II: 11:00-2:30pm
132	Conover	David	Cone beam breast CT imaging	Imaging	Imaging Approaches to Cancer Detection	Group I: 8:00-10:30am
289	Cote	Richard	Development of a Membrane Microfilter Device for Capture and Characterization of Circulating Tumor Cells (CTC) in Blood	Biospecimens	Biomarkers for Breast Cancer	Group II: 11:00-2:30pm
267	Couch	Fergus	Breast cancer risk associated with BRCA1 and BRCA2 variants of uncertain significance	Biospecimens	Biomarkers for Breast Cancer	Group II: 11:00-2:30pm
336	Coukos	George	Modulation of Tumor Endothelium for Successful Immunotherapy of Ovarian Cancer	IRMs	Cellular Therapy for Immune Response Modification	Group II: 11:00-2:30pm
157	Craft	David	Multi-criteria optimization of intensity-modulated radiation therapy	Devices	Ionizing and Non-Ionizing Radiation	Group I: 8:00-10:30am
453	Cramer	Daniel	Validation of ovarian cancer biomarkers in pre-diagnostic specimens from the PLCO Trial	Biospecimens	Biomarkers for Early Detection	Group III: 3:00-5:30pm
454	Cramer	Daniel	Advances in understanding precursor lesions for high grade serous cancers	Biospecimens	Biomarkers for Early Detection	Group III: 3:00-5:30pm
467	Cramer	Daniel	Anti-MUC1 antibody levels and risk for ovarian cancer in the Nurses' Health Studies	Biospecimens	Biomarkers for Early Detection	Group III: 3:00-5:30pm
357	Curley	Mike	Development of Saline Enhanced Radiofrequency Ablation for Treatment of Liver Tumors	Devices	Devices for Surgery Ablation and Biopsy	Group II: 11:00-2:30pm
115	Czerniak	Bogdan	Aurora Kinase A as a Biomarker for the Detection of Bladder Cancer	Biospecimens	Biomarkers for Prostate & Bladder Cancers	Group I: 8:00-10:30am
410	Czerniak	Bogdan	Understanding the Development of Human Bladder Can	Agents	Integrative Biology: Bench to Bedside	Group III: 3:00-5:30pm
251	Dang	Thao	Strategies In Targeting Notch3 In Lung Cancer	Agents	Targeting Head, Neck & Lung Cancers	Group II: 11:00-2:30pm
501	Dasgupta	Santanu	Tracing clonal lung tumor evolution through mitochondrial footprints	Biospecimens	Biomarkers for Lung Cancer Detection & Therapy	Group III: 3:00-5:30pm
179	Dashwood	Rod	Translational Chemoprevention Studies with Chlorophylls	Lifestyle	Dietary Components in Cancer Prevention & Control	Group I: 8:00-10:30am

Poster #	Submitter's Last Name	Submitter's First Name	Title	Assigned Pathway	Poster Discussion Session	Concurrent Session
439	Davidson	Nancy	Targeting epigenetic modifications in breast cancer	Agents	Therapeutic Targeting in Pancreatic & Breast Cancer	Group III: 3:00-5:30pm
425	Day	Billy	Improved synthesis and antitumor efficacy of 6-epi-dictyostatin in MDA-MB231 human breast cancer xenograft-bearing mice	Agents	Therapeutic Targeting in Pancreatic & Breast Cancer	Group III: 3:00-5:30pm
322	Day	Chi-Ping	Development of Traceable Syngeneic Mouse Tumor Models with Bifunctional Cell-labeling Lentiviral Vectors	Imaging	Imaging and Cancer Therapeutics	Group II: 11:00-2:30pm
270	De Michele	Angela	Host Polymorphisms in the IL6 Promoter Predict Poor Outcome in Patients with ER-Positive, Node-Positive Breast Cancer	Biospecimens	Biomarkers for Breast Cancer	Group II: 11:00-2:30pm
424	De Michele	Angela	Host Polymorphisms in the IL6 Promoter Predict Poor Outcome in Patients with ER-Positive, Node-Positive Breast Cancer	Agents	Therapeutic Targeting in Pancreatic & Breast Cancer	Group III: 3:00-5:30pm
161	Demmy	Todd	Surrogate Molecular Markers for Deposited Dose in Photodynamic Therapy with the New Photosensitizer HPPH	Devices	Ionizing and Non-Ionizing Radiation	Group I: 8:00-10:30am
227	Denmeade	Sam	A Novel Targeted Prostate-Specific Membrane Antigen (PSMA) Activated Thapsigargin Prodrug Produces Substantial Regression and Prolonged Growth Inhibition of Human Cancer Xenografts	Agents	New Agents for the Treatment & Prevention of Prostate Cancer	Group II: 11:00-2:30pm
244	Dennis	Philip	The role of lung-derived regulatory T cells in Kras-driven lung tumorigenesis	Agents	Targeting Head, Neck & Lung Cancers	Group II: 11:00-2:30pm
171	Desjardins	Annick	Update on survival from the original phase II trial of bevacuzimab and irinotecan in recurrent malignant gliomas	Devices	Ionizing and Non-Ionizing Radiation	Group I: 8:00-10:30am
151	Dhabhar	Firdaus	Activating Endogenous Mechanisms That Enhance Anti-Tumor Immune Responses	IRMs	Antibodies, Cytokines, & Viruses	Group I: 8:00-10:30am
381	Dhabhar	Firdaus	Activating Endogenous Mechanisms That Enhance Anti-Tumor Immune Responses	Lifestyle	Biobehavioral Mechanisms in Cancer Progression & Control	Group II: 11:00-2:30pm
140	Dimitrov	Dimiter	Human Monoclonal Antibodies Targeting Components of the IGF System and other Cancer-related Proteins	IRMs	Antibodies, Cytokines, & Viruses	Group I: 8:00-10:30am
124	Djuth	Frank	Diagnosis of Cancer with High-Resolution Ultrasound	Imaging	Imaging Approaches to Cancer Detection	Group I: 8:00-10:30am
38	Dolan	Eileen	Use of International HapMap Cell Lines for Pharmacogenomic Discovery	Agents	Cancer Stem Cell, Gene Expression, & Epigenetic Targets	Group I: 8:00-10:30am
340	Doti	Gianpietro	Chimeric Antigen Receptor (CAR)-modified Virus Specific T lymphocytes for Neuroblastoma	IRMs	Cellular Therapy for Immune Response Modification	Group II: 11:00-2:30pm
515	Dubinnett	Steven	The Zinc-Finger E-Box-Binding Transcriptional Repressor Snail Links Inflammation, Angiogenesis, and EMT in Human NSCLC	Biospecimens	Biomarkers for Lung Cancer Detection & Therapy	Group III: 3:00-5:30pm
341	Dudas	Steven	On-Chip Diagnostic Immunoassays of Panels of Bioselected Tumor Antigens: Binding to Serum Autoantibodies for the Early Detection of Cancer	IRMs	Cellular Therapy for Immune Response Modification	Group II: 11:00-2:30pm
342	Dudley	Mark	Adoptive Cell Therapy for Patients with Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens	IRMs	Cellular Therapy for Immune Response Modification	Group II: 11:00-2:30pm
63	Elenitoba-Johnson	Kojo	Deregulation of the Insulin-like Growth Factor Type 1 Receptor (IGF-1R) in Transformed Follicular Lymphomas: Implications for Novel Therapy	Biospecimens	Biomarkers for Hematologic Malignancies & Pediatric Cancer	Group I: 8:00-10:30am
89	Ellis	Matthew	Development of the ζ PAM50 ζ intrinsic subtype assay: Potential as a prognostic assay for patients with early stage breast cancer	Biospecimens	-Omic Technology in Biomarker Discovery & Development	Group I: 8:00-10:30am
272	Ellis	Matthew	Development of the ζ PAM50 ζ intrinsic subtype assay: Potential as a prognostic assay for patients with early stage breast cancer	Biospecimens	Biomarkers for Breast Cancer	Group II: 11:00-2:30pm
475	El-Rifai	Wael	Molecular Targets in Upper GI Cancer	Biospecimens	Biomarkers: Esophagus, Colon, and Liver Cancers	Group III: 3:00-5:30pm
180	Erdman	John	Tomatoes, Tomato Carotenoids and Prostate Cancer	Lifestyle	Dietary Components in Cancer Prevention & Control	Group I: 8:00-10:30am
228	Erdman	John	Tomatoes, Tomato Carotenoids and Prostate Cancer	Agents	New Agents for the Treatment & Prevention of Prostate Cancer	Group II: 11:00-2:30pm
273	Fabian	Carol	Inhibition of Aromatase for Breast Cancer Prevention in Postmenopausal Women on Hormone Replacement Therapy	Biospecimens	Biomarkers for Breast Cancer	Group II: 11:00-2:30pm
526	Fakhrai	Habib	Phase II Clinical Trial in NSCLC With Lucanix ζ , a Cocktail of Four TGF- β 2 Antisense Gene Modified Tumor Cells	IRMs	Cancer Vaccines	Group III: 3:00-5:30pm
371	Fang	Carolyn	Mindfulness-based intervention to enhance cell-mediated immune response to HPV among women at risk for cervical cancer	Lifestyle	Biobehavioral Mechanisms in Cancer Progression & Control	Group II: 11:00-2:30pm
43	Farrar	William	Molecular Targeting the Biologics of Prostate Cancer Stem Cells	Agents	Cancer Stem Cell, Gene Expression, & Epigenetic Targets	Group I: 8:00-10:30am
245	Farrell	Nick	Clinically Relevant Platinum Agents	Agents	Targeting Head, Neck & Lung Cancers	Group II: 11:00-2:30pm
455	Feng	Ziding	The Early Detection Research Network (EDRN) Biomarker Validation Studies - Design and Execution	Biospecimens	Biomarkers for Early Detection	Group III: 3:00-5:30pm
543	Ferris	Bob	Phase I Adjuvant p53 Based Immunotherapy for Head and Neck Cancer	IRMs	Cancer Vaccines	Group III: 3:00-5:30pm
527	Finn	Olivera	Translational Research Program in Dendritic Cell Biology and Therapy	IRMs	Cancer Vaccines	Group III: 3:00-5:30pm
218	Fisher	Paul	mda-7/IL-24: Broad-spectrum gene therapeutic for localized and disseminated cancers	Agents	Drug Delivery & Gene Therapy	Group II: 11:00-2:30pm
284	Fisher	Susan	Mining cancer-specific alterations in alternative splicing and glycosylation for potential biomarkers that enable the early detection of metastasis-prone breast cancers	Biospecimens	Biomarkers for Breast Cancer	Group II: 11:00-2:30pm
299	Flaherty	Keith	Defining genetic subgroups of melanoma and determining optimal targeted therapy: parallel preclinical studies and clinical trials	Biospecimens	Prognostic & Predictive Biomarkers	Group II: 11:00-2:30pm
40	Flaherty	Keith	Defining genetic subgroups of melanoma and determining optimal targeted therapy: parallel preclinical studies and clinical trials	Agents	Cancer Stem Cell, Gene Expression, & Epigenetic Targets	Group I: 8:00-10:30am
358	Flynn	Edward	Development and Characterization of a Magnetic Biopsy Needle and Magnetic Nanoparticles for Sensitive Detection of Cancer Cells in the Bone Marrow	Devices	Devices for Surgery Ablation and Biopsy	Group II: 11:00-2:30pm

Poster #	Submitter's Last Name	Submitter's First Name	Title	Assigned Pathway	Poster Discussion Session	Concurrent Session
126	Follen	Michele	Optical Technologies for Cervical Neoplasia	Imaging	Imaging Approaches to Cancer Detection	Group I: 8:00-10:30am
359	Follen	Michele	Optical Technologies for Cervical Neoplasia	Devices	Devices for Surgery Ablation and Biopsy	Group II: 11:00-2:30pm
142	Forman	Steve	City of Hope Lymphoma SPORE	IRMs	Antibodies, Cytokines, & Viruses	Group I: 8:00-10:30am
528	Forman	Steve	Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancy	IRMs	Cancer Vaccines	Group III: 3:00-5:30pm
162	Foster	Tom	Optical Spectroscopy Informs Clinical Translation of Photodynamic Therapy	Devices	Ionizing and Non-Ionizing Radiation	Group I: 8:00-10:30am
163	Fraass	Benedick	Individualization and Optimization of High Dose Conformal Radiation Therapy	Devices	Ionizing and Non-Ionizing Radiation	Group I: 8:00-10:30am
53	Frank	Markus	Identification of cells initiating human melanomas	Agents	Cancer Stem Cell, Gene Expression, & Epigenetic Targets	Group I: 8:00-10:30am
127	Franklin	Wilbur	Biomarkers Of Premalignancy And Detection of Early Lung Cancer	Imaging	Imaging Approaches to Cancer Detection	Group I: 8:00-10:30am
502	Franklin	Wilbur	Biomarkers Of Premalignancy And Detection of Early Lung Cancer	Biospecimens	Biomarkers for Lung Cancer Detection & Therapy	Group III: 3:00-5:30pm
143	Freytag	Svend	Late Stage Clinical Development of Gene Therapy Approach for Prostate Cancer	IRMs	Antibodies, Cytokines, & Viruses	Group I: 8:00-10:30am
201	Freytag	Svend	Late Stage Clinical Development of Gene Therapy Approach for Prostate Cancer	Agents	Drug Delivery & Gene Therapy	Group II: 11:00-2:30pm
181	Fuchs	Charles	Dietary and Lifestyle Determinants of Colon Cancer Recurrence and Survival	Lifestyle	Dietary Components in Cancer Prevention & Control	Group I: 8:00-10:30am
3	Fueyo	Juan	Translational development of Delta-24-RGD for the treatment of patients with malignant gliomas	Agents	Biochemical Targets & Drug Screening	Group I: 8:00-10:30am
202	Fukuda	Minoru	Targeted drug delivery to tumor vasculature by a carbohydrate-mimicry peptide	Agents	Drug Delivery & Gene Therapy	Group II: 11:00-2:30pm
477	Gerner	Eugene	Risk Assessment for Combination Chemoprevention for Recurrent Colon Polyps	Biospecimens	Biomarkers: Esophagus, Colon, and Liver Cancers	Group III: 3:00-5:30pm
128	Giger	Maryellen	Image-based Markers of Breast Cancer Risk	Imaging	Imaging Approaches to Cancer Detection	Group I: 8:00-10:30am
465	Gildersleeve	Jeffrey	Profiling Serum Antibodies with Carbohydrate Antig	Biospecimens	Biomarkers for Early Detection	Group III: 3:00-5:30pm
4	Gillespie	Yancey	Anti-angiogenic Therapy of Anaplastic Gliomas Using Thrombospondin Peptide and Radiation	Agents	Biochemical Targets & Drug Screening	Group I: 8:00-10:30am
301	Gimotty	Phyllis	The Prognostic Significance of Ki67 Expression in Stage I/II Invasive Cutaneous Melanoma	Biospecimens	Prognostic & Predictive Biomarkers	Group II: 11:00-2:30pm
166	Gladson	Candece	Plasminogen Kringle 5 Induces Apoptosis of Brain Microvessel Endothelial Cells: Sensitization by Radiation and Requirement for GRP78 and LRP1	Devices	Ionizing and Non-Ionizing Radiation	Group I: 8:00-10:30am
275	Glass	Andrew	The NCI-Cooperative Breast Cancer Tissue Resource (CBCTR)	Biospecimens	Biomarkers for Breast Cancer	Group II: 11:00-2:30pm
164	Glatstein	Eli	Photodynamic Therapy for Serosal Malignancies: An integrated bedside to bench approach to translational research	Devices	Ionizing and Non-Ionizing Radiation	Group I: 8:00-10:30am
229	Gleave	Martin	Targeting the Multi-functional Cytoprotective Chaperone Hsp27 in Castrate Resistant Prostate Cancer using OGX-427: Preclinical and Phase I Clinical Observations.	Agents	New Agents for the Treatment & Prevention of Prostate Cancer	Group II: 11:00-2:30pm
478	Godfrey	Tony	Integrated Genomic Analysis of Esophageal Adenocarcinoma	Biospecimens	Biomarkers: Esophagus, Colon, and Liver Cancers	Group III: 3:00-5:30pm
427	Goetz	Matthew	Endoxifen, but not 4-hydroxytamoxifen (4HT), degrades the estrogen receptor (ER) in breast cancer cells. An impetus for endoxifen drug development?	Agents	Therapeutic Targeting in Pancreatic & Breast Cancer	Group III: 3:00-5:30pm
470	Goggins	Michael	Serum Fatty Acid Synthase as a marker of pancreatic neoplasia	Biospecimens	Biomarkers for Early Detection	Group III: 3:00-5:30pm
144	Goldenberg	David	Antibody-targeted therapeutics for B-cell malignancies: From bench to clinic.	IRMs	Antibodies, Cytokines, & Viruses	Group I: 8:00-10:30am
386	Goldenberg	David	Antibody-targeted therapeutics for B-cell malignancies: From bench to clinic.	Agents	Novel Targets in Hematological Malignancies	Group III: 3:00-5:30pm
257	Grandis	Jennifer	Development of a Transcription Factor Decoy Targeting STAT3: Implementation of a Phase 0 Trial in Head and Neck Cancer	Agents	Targeting Head, Neck & Lung Cancers	Group II: 11:00-2:30pm
387	Grant	Steven	Potentiation of histone deacetylase inhibitor activity in hematopoietic malignancies by agents that interrupt the NF-kB pathway	Agents	Novel Targets in Hematological Malignancies	Group III: 3:00-5:30pm
70	Graubert	Tim	Whole Genome Sequencing of an Acute Myeloid Leukemia Genome with Normal Cytogenetics	Biospecimens	Biomarkers for Hematologic Malignancies & Pediatric Cancer	Group I: 8:00-10:30am
269	Gray	Joe W.	In vitro Systems Approaches to Identification of Molecular Markers that Predict Clinical Response in Breast Cancer	Biospecimens	Biomarkers for Breast Cancer	Group II: 11:00-2:30pm
391	Grever	Mike	Silvestrol: A Novel B-cell Selective Agent for Potential Use in Leukemias and Lymphomas	Agents	Novel Targets in Hematological Malignancies	Group III: 3:00-5:30pm
6	Grever	Mike	Ohio State Phase I U01 Program Michael Grever, MD, John Byrd, MD., Thomas Lin, MD, PhD., Guido Marcucci, MD., William Blum, MD, James Thomas, MD, PhD., Miguel Villalona, MD, Mitch Phelps, PhD, James D	Agents	Biochemical Targets & Drug Screening	Group I: 8:00-10:30am
310	Grimm	Elizabeth	Association of VEGF Polymorphisms with Primary Melanoma Tumor Thickness and Ulceration	Biospecimens	Prognostic & Predictive Biomarkers	Group II: 11:00-2:30pm
432	Grubbs	Clint	Effects of Methyl Derivatives of the Rexinoid UAB3	Agents	Therapeutic Targeting in Pancreatic & Breast Cancer	Group III: 3:00-5:30pm
182	Hakim	Iman	Chemoprevention of Lung Carcinogenesis Using Green Tea:	Lifestyle	Dietary Components in Cancer Prevention & Control	Group I: 8:00-10:30am
246	Hakim	Iman	Chemoprevention of Lung Carcinogenesis Using Green Tea:	Agents	Targeting Head, Neck & Lung Cancers	Group II: 11:00-2:30pm
348	Halaban	Ruth	Plasma-based ELISA assay to monitor melanoma patients for recurrence and response to systemic therapy	IRMs	Cellular Therapy for Immune Response Modification	Group II: 11:00-2:30pm
90	Hanash	Sam	Novel approaches to cancer biomarker discovery using proteomics	Biospecimens	-Omic Technology in Biomarker Discovery & Development	Group I: 8:00-10:30am
203	Hansen	Brian	Lung Cancer Treatment with Pulmonary Aerosol Drug Delivery System	Agents	Drug Delivery & Gene Therapy	Group II: 11:00-2:30pm
372	Harrington	Mary	Do cytokines TGF- α and Neuregulin-1 suppress circadian clock output in mice? A model for cancer-related fatigue.	Lifestyle	Biobehavioral Mechanisms in Cancer Progression & Control	Group II: 11:00-2:30pm
493	Harris	Curt	MicroRNA expression patterns are associated with prognosis and therapeutic outcome in colon adenocarcinoma	Biospecimens	Biomarkers: Esophagus, Colon, and Liver Cancers	Group III: 3:00-5:30pm
360	Hata	Noby	MR-Guided Thermal Therapies	Devices	Devices for Surgery Ablation and Biopsy	Group II: 11:00-2:30pm
409	Haura	Eric	Discerning mechanisms of action and biomarkers for Dasatinib through combined chemical and shotgun phosphoproteomics	Agents	Integrative Biology: Bench to Bedside	Group III: 3:00-5:30pm

Poster #	Submitter's Last Name	Submitter's First Name	Title	Assigned Pathway	Poster Discussion Session	Concurrent Session
504	Heist	Rebecca	Circulating 25-hydroxyvitamin D, VDR Polymorphisms, and Survival in Advanced Non-Small Cell Lung Cancer	Biospecimens	Biomarkers for Lung Cancer Detection & Therapy	Group III: 3:00-5:30pm
107	Henning	Susanne	Tea Polyphenols in Chemoprevention of Prostate Cancer	Biospecimens	Biomarkers for Prostate & Bladder Cancers	Group I: 8:00-10:30am
230	Henning	Susanne	Tea Polyphenols in Chemoprevention of Prostate Cancer	Agents	New Agents for the Treatment & Prevention of Prostate Cancer	Group II: 11:00-2:30pm
344	Herlyn	Meenhard	Tumor-initiating melanoma cells require new strategies for therapy	IRMs	Cellular Therapy for Immune Response Modification	Group II: 11:00-2:30pm
91	Herman	James G	Integrated DNA Methylation Analysis of Glioblastoma: The TCGA Consortium	Biospecimens	-Omic Technology in Biomarker Discovery & Development	Group I: 8:00-10:30am
204	Herschman	Harvey	Combined transductional untargeting/retargeting and transcriptional restriction enhances Ad-mediated gene targeting and therapy for hepatic colorectal cancer tumors.	Agents	Drug Delivery & Gene Therapy	Group II: 11:00-2:30pm
345	Heslop	Helen	Treatment Of Epstein Barr Virus Positive Nasopharyngeal Carcinoma With Adoptively Transferred Cytotoxic T Lymphocytes	IRMs	Cellular Therapy for Immune Response Modification	Group II: 11:00-2:30pm
296	Heymach	John	Correlation of cytokine and angiogenic factor (C/AF) profiles with clinical outcomes following induction chemotherapy in head and neck squamous cell cancer (HN)	Biospecimens	Prognostic & Predictive Biomarkers	Group II: 11:00-2:30pm
196	Hilakivi-Clarke	Leena	Mammary progenitor cells as targets of dietary prevention of breast cancer	Lifestyle	Dietary Components in Cancer Prevention & Control	Group I: 8:00-10:30am
514	Hirsch	Fred	A PROTEOMIC APPROACH TO EARLY DETECTION OF LUNG CANCER	Biospecimens	Biomarkers for Lung Cancer Detection & Therapy	Group III: 3:00-5:30pm
183	Ho	Emily	Dietary histone deacetylase inhibitors for cancer prevention: from cells to mice to man.	Lifestyle	Dietary Components in Cancer Prevention & Control	Group I: 8:00-10:30am
304	Hoadley	Katie	Identification of Molecular Subtypes of Glioblastoma	Biospecimens	Prognostic & Predictive Biomarkers	Group II: 11:00-2:30pm
388	Hoffman	Ronald	The Myeloproliferative Disorders Research Consortium (MPD-RC)	Agents	Novel Targets in Hematological Malignancies	Group III: 3:00-5:30pm
66	Hoffman	Ronald	The Myeloproliferative Disorders Research Consortium (MPD-RC)	Biospecimens	Biomarkers for Hematologic Malignancies & Pediatric Cancer	Group I: 8:00-10:30am
361	Hoon	Dave	Multicenter Selective Lymphadenectomy Trials for Melanoma	Devices	Devices for Surgery Ablation and Biopsy	Group II: 11:00-2:30pm
109	Hoque	Mohammad	Methylation pattern of multiple genes in urine sediment DNA from bladder cancer cases and controls by quantitative methylation specific PCR (QMSP)	Biospecimens	Biomarkers for Prostate & Bladder Cancers	Group I: 8:00-10:30am
8	Horwitz	Susan Band	A Multifaceted Program for the Development of Discodermolide: A Microtubule-Stabilizing Agent with Unique Additional Properties.	Agents	Biochemical Targets & Drug Screening	Group I: 8:00-10:30am
9	Houghton	Peter	Simultaneous Targeting of mTORC1 and the IGF-1 Receptor for Treatment of Childhood Sarcomas	Agents	Biochemical Targets & Drug Screening	Group I: 8:00-10:30am
346	Huang	Christene	Genetics and Mechanisms of DLI Effects Following Non-myeloablative HCT	IRMs	Cellular Therapy for Immune Response Modification	Group II: 11:00-2:30pm
430	Hung	Mien	Targeted BIKDD Expression Promotes the Therapeutic Efficacy of Lapatinib for Breast Cancer Treatment	Agents	Therapeutic Targeting in Pancreatic & Breast Cancer	Group III: 3:00-5:30pm
10	Hung	Mien	Akt, IKK and Erk, three Oncogenic Kinases and Cancers	Agents	Biochemical Targets & Drug Screening	Group I: 8:00-10:30am
220	Hung	Mien Chie	Development of Targeted Cancer Gene Therapy	Agents	Drug Delivery & Gene Therapy	Group II: 11:00-2:30pm
87	Hunter	Kent	Inherited susceptibility to tumor progression and metastasis	Biospecimens	-Omic Technology in Biomarker Discovery & Development	Group I: 8:00-10:30am
42	Hurley	Laurence	Small Molecule Repression of c-Myc Gene Expression in Validated Tumor Types by Targeting Secondary DNA Structures	Agents	Cancer Stem Cell, Gene Expression, & Epigenetic Targets	Group I: 8:00-10:30am
146	Hwu	Patrick	Activation of Plasmacytoid Dendritic Cells with TLR Agonists in Order to Induce Improved Antitumor Immune Responses Against Melanoma	IRMs	Antibodies, Cytokines, & Viruses	Group I: 8:00-10:30am
279	Iglehart	J. Dirk	Copy Number Gain at 8q22 in Breast Cancer is Associated with Poor Outcome and Chemoresistance	Biospecimens	Biomarkers for Breast Cancer	Group II: 11:00-2:30pm
458	Iliopoulos	Othon	A SIGNAL-DEPENDANT ORGAN-RESTRICTED (SIDOR) APPROACH FOR DISCOVERY OF CANDIDATE RENAL CELL CARCINOMA (RCC) BIOMARKERS	Biospecimens	Biomarkers for Early Detection	Group III: 3:00-5:30pm
530	Ingle	Jim	Development of a Breast Cancer Vaccine using Glycosylated and Anchor-Modified MUC1 Peptides	IRMs	Cancer Vaccines	Group III: 3:00-5:30pm
45	Issa	Jean-Pierre	Epigenetics and chemotherapy resistance in acute myelogenous leukemia	Agents	Cancer Stem Cell, Gene Expression, & Epigenetic Targets	Group I: 8:00-10:30am
529	Ittmann	Michael	Genetically Enhanced Dendritic Cell-Based Immunotherapy for Cancer	IRMs	Cancer Vaccines	Group III: 3:00-5:30pm
44	Jacob	Samson	DNA METHYLATION AND CHROMATIN MODIFICATIONS: MECHANISMS AND APPLICATIONS IN CANCER THERAPY	Agents	Cancer Stem Cell, Gene Expression, & Epigenetic Targets	Group I: 8:00-10:30am
64	Jaffe	Elaine	Histiocytic/dendritic sarcomas clonally related to follicular lymphoma: evidence for lineage plasticity in mature human B-cells	Biospecimens	Biomarkers for Hematologic Malignancies & Pediatric Cancer	Group I: 8:00-10:30am
349	Jaffee	Elizabeth	Identification and Validation of Immune Biomarkers as Predictors of Vaccine Response.	IRMs	Cellular Therapy for Immune Response Modification	Group II: 11:00-2:30pm
547	Jaffee	Elizabeth	Development of Antigen Targeted Vaccines and Immune Checkpoint Inhibitors for Cancer Therapy	IRMs	Cancer Vaccines	Group III: 3:00-5:30pm
306	Jain	Rakesh	Normalization of the tumor microenvironment for therapy: Bench to bedside and back	Biospecimens	Prognostic & Predictive Biomarkers	Group II: 11:00-2:30pm
404	Jain	Rakesh	Normalization of the tumor microenvironment for therapy: Bench to bedside and back	Agents	Integrative Biology: Bench to Bedside	Group III: 3:00-5:30pm
67	Jelinek	Diane	Studies on Monoclonal Gammopathies	Biospecimens	Biomarkers for Hematologic Malignancies & Pediatric Cancer	Group I: 8:00-10:30am
325	Jeraj	Robert	Pharmacodynamic Study of Sunitinib Therapy Using FLT PET Imaging	Imaging	Imaging and Cancer Therapeutics	Group II: 11:00-2:30pm
307	Johnson	David	Urine PGE2 Metabolite as a Possible Biomarker in Patients with Non-Small Cell Lung Cancer	Biospecimens	Prognostic & Predictive Biomarkers	Group II: 11:00-2:30pm
5	Jong	Ling	Preclinical Development of SR13668, A Novel Dietary Indole Analog for Cancer Prevention and Therapy	Agents	Biochemical Targets & Drug Screening	Group I: 8:00-10:30am

Poster #	Submitter's Last Name	Submitter's First Name	Title	Assigned Pathway	Poster Discussion Session	Concurrent Session
197	Kabanov	Sasha	Polymer micelles: From bench to the bedside	Agents	Drug Delivery & Gene Therapy	Group II: 11:00-2:30pm
347	Kalinski	Pawel	Semi-Continuous Intralymphatic Infusion of Dendritic Cells as Therapy of Advanced Melanoma (UPCI 03-118)	IRMs	Cellular Therapy for Immune Response Modification	Group II: 11:00-2:30pm
308	Kashani-Sabet	Mohammed	Validation of Genomic Targets in Melanoma	Biospecimens	Prognostic & Predictive Biomarkers	Group II: 11:00-2:30pm
405	Kashani-Sabet	Mohammed	Validation of Genomic Targets in Melanoma	Agents	Integrative Biology: Bench to Bedside	Group III: 3:00-5:30pm
290	Keyomarsi	Khandan	The Low Molecular Weight Forms of Cyclin E are Tumor Specific in Breast Cancer and Tumorigenic in Human Mammary Epithelial Cells	Biospecimens	Biomarkers for Breast Cancer	Group II: 11:00-2:30pm
406	Khanna	Chand	A Comparative Approach to Cancer Biology and Therapy	Agents	Integrative Biology: Bench to Bedside	Group III: 3:00-5:30pm
248	Khuri	Fadlo	Targeting mTOR Through Integrated Pathway Approach to Enhance the Therapeutic Efficacy in Lung Cancer	Agents	Targeting Head, Neck & Lung Cancers	Group II: 11:00-2:30pm
323	Khuri	Fadlo	Multifunctional and Long-Circulating Nanoparticles for In Vivo Cancer Imaging and Therapy	Imaging	Imaging and Cancer Therapeutics	Group II: 11:00-2:30pm
428	Killary	Ann	A Genomic Pathways Approach to Biomarker Discovery for the Early Detection and Risk Assessment of Pancreatic Cancer	Agents	Therapeutic Targeting in Pancreatic & Breast Cancer	Group III: 3:00-5:30pm
119	Kim	Jeri	Tissue Effects of Selenium and Vitamin E in Prostate Cancer	Biospecimens	Biomarkers for Prostate & Bladder Cancers	Group I: 8:00-10:30am
239	Kim	Jeri	Tissue Effects of Selenium and Vitamin E in Prostate Cancer	Agents	New Agents for the Treatment & Prevention of Prostate Cancer	Group II: 11:00-2:30pm
11	Kinghorn	Douglas	Discovery of Anticancer Agents of Diverse Natural Origin	Agents	Biochemical Targets & Drug Screening	Group I: 8:00-10:30am
221	Kinkade	Carolyn	Developing combination therapies for hormone-refractory prostate cancer in a pre-clinical mouse model of the disease	Agents	New Agents for the Treatment & Prevention of Prostate Cancer	Group II: 11:00-2:30pm
390	Kipps	Thomas	Chronic Lymphocytic Leukemia Research Consortium	Agents	Novel Targets in Hematological Malignancies	Group III: 3:00-5:30pm
356	Kirkwood	John	Clinical and Serologic Markers of Benefit in Metastatic Melanoma Treated with Combination Immunotherapy of IFNa-2b (HDI) and Anti-CTLA4 Blockade: Preliminary Data	IRMs	Cellular Therapy for Immune Response Modification	Group II: 11:00-2:30pm
459	Klug	Chris	Identification of Serum Biomarkers of Early-Stage Pancreatic Neoplasia using Genetically-Defined Mouse Models of Pancreatic Cancer	Biospecimens	Biomarkers for Early Detection	Group III: 3:00-5:30pm
407	Kohn	Elise	COMBINATORIAL THERAPY WITH SIGNAL INHIBITORS IN SERIES: Clinical trial and proof of concept translational studies	Agents	Integrative Biology: Bench to Bedside	Group III: 3:00-5:30pm
206	Kopecek	Jindrich	Double-Targeted Macromolecular Therapeutics for the Treatment of Prostate Cancer	Agents	Drug Delivery & Gene Therapy	Group II: 11:00-2:30pm
426	Korde	Larissa	Effect of Exemestane on Bone Mineral Density in Postmenopausal Women at Risk for Breast Cancer: Preliminary Analysis	Agents	Therapeutic Targeting in Pancreatic & Breast Cancer	Group III: 3:00-5:30pm
185	Kristal	Bruce	Biomarkers for caloric restriction in rats: biomarkers for cancer risk in humans?	Lifestyle	Dietary Components in Cancer Prevention & Control	Group I: 8:00-10:30am
277	Kristal	Bruce	Biomarkers for caloric restriction in rats: biomarkers for cancer risk in humans?	Biospecimens	Biomarkers for Breast Cancer	Group II: 11:00-2:30pm
324	Krohn	Kenneth	Imaging Cancer Treatment Response: PET Translational Research at the University of Washington	Imaging	Imaging and Cancer Therapeutics	Group II: 11:00-2:30pm
403	Krohn	Kenneth	Imaging Cancer Treatment Response: PET Translational Research at the University of Washington	Agents	Integrative Biology: Bench to Bedside	Group III: 3:00-5:30pm
187	Kuhajda	Francis	Fatty Acid Synthase Inhibition for Ovarian Cancer	Lifestyle	Dietary Components in Cancer Prevention & Control	Group I: 8:00-10:30am
266	Kummel	Andrew	Automated Rapid Analysis of Surgical Margins of Breast	Biospecimens	Biomarkers for Breast Cancer	Group II: 11:00-2:30pm
408	Kurzrock	Razelle	Strategies for Phase I Development of Targeted Anti-Cancer Agents	Agents	Integrative Biology: Bench to Bedside	Group III: 3:00-5:30pm
250	Kwiatkowski	Davide	Role of the TSC1/TSC2 Genes in Lung Cancer	Agents	Targeting Head, Neck & Lung Cancers	Group II: 11:00-2:30pm
327	Lacy	Jeff	Instant Kit Synthesis of ⁶² Cu Radiopharmaceuticals Employing a Distributable ⁶² Zn/ ⁶² Cu Microgenerator	Imaging	Imaging and Cancer Therapeutics	Group II: 11:00-2:30pm
81	Ladanyi	Marc	The TCGA Cancer Genome Characterization Center (CGCC) at MSKCC: High Resolution Genomic Copy Number Analysis of the First 215 Glioblastoma Samples	Biospecimens	-Omic Technology in Biomarker Discovery & Development	Group I: 8:00-10:30am
129	Lam	Stephen	Evaluation Of Lung Cancer Chemopreventive Agents In Phase II Clinical Trials	Imaging	Imaging Approaches to Cancer Detection	Group I: 8:00-10:30am
506	Lam	Stephen	Evaluation Of Lung Cancer Chemopreventive Agents In Phase II Clinical Trials	Biospecimens	Biomarkers for Lung Cancer Detection & Therapy	Group III: 3:00-5:30pm
263	Lampe	Johanna	Daidzein-Metabolizing Phenotypes Among Premenopausal Women in the United States: Relationship to Health and Lifestyle Factors and Impact on Breast Density and Sex Steroid Measures.	Biospecimens	Biomarkers for Breast Cancer	Group II: 11:00-2:30pm
98	Larson	Dale	Preservation of sample integrity in biobanked samples using a frozen sample aliquotter	Biospecimens	-Omic Technology in Biomarker Discovery & Development	Group I: 8:00-10:30am
68	Lau	Ching	Use of Genomic Profiling to Identify Prognostic Markers for Ependymomas	Biospecimens	Biomarkers for Hematologic Malignancies & Pediatric Cancer	Group I: 8:00-10:30am
253	Lawrence	Ted	The combination of EGFR inhibitors with gemcitabine and radiation in pancreatic cancer	Agents	Targeting Head, Neck & Lung Cancers	Group II: 11:00-2:30pm
123	Lee	Chung	TGF-beta induced vimentin expression predicts biochemical recurrence following radical prostatectomy	Biospecimens	Biomarkers for Prostate & Bladder Cancers	Group I: 8:00-10:30am
13	Lee	Kuo-Hsiung	Plant-derived Natural Product Analogs as Anticancer Clinical Trials Agents	Agents	Biochemical Targets & Drug Screening	Group I: 8:00-10:30am
14	Lee	Moses	Development of ML-970 as a Potential Anticancer Drug	Agents	Biochemical Targets & Drug Screening	Group I: 8:00-10:30am
264	Lee	Oukseub	Disparity between serum and nipple aspirate fluid (NAF) estradiol concentrations during the menstrual cycle	Biospecimens	Biomarkers for Breast Cancer	Group II: 11:00-2:30pm
497	Lenburg	Marc	Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer.	Biospecimens	Biomarkers for Lung Cancer Detection & Therapy	Group III: 3:00-5:30pm
186	Lerman	Caryn	Translating Neuroscience, Pharmacology and Genetics to Improve Therapy for Nicotine Dependence	Lifestyle	Dietary Components in Cancer Prevention & Control	Group I: 8:00-10:30am
69	Levis	Mark	Assessment of in vivo target inhibition through the use of a plasma inhibitory activity (PIA) assay.	Biospecimens	Biomarkers for Hematologic Malignancies & Pediatric Cancer	Group I: 8:00-10:30am

Poster #	Submitter's Last Name	Submitter's First Name	Title	Assigned Pathway	Poster Discussion Session	Concurrent Session
93	Liebler	Dan	Development and standardization of liquid chromatography-tandem mass spectrometry methods for protein biomarker discovery and verification in tissues	Biospecimens	-Omic Technology in Biomarker Discovery & Development	Group I: 8:00-10:30am
111	Lin	Sue-Hwa	Soluble ErbB3 Levels in Bone Marrow and Plasma of Men with Prostate Cancer	Biospecimens	Biomarkers for Prostate & Bladder Cancers	Group I: 8:00-10:30am
461	Linehan	W. Marston	Molecular Targeting of Kidney Cancer Gene Pathways	Biospecimens	Biomarkers for Early Detection	Group III: 3:00-5:30pm
94	Liu	Alvin	EDRN Biomarker Development Lab: Prostate and Bladder Cancer Genes	Biospecimens	-Omic Technology in Biomarker Discovery & Development	Group I: 8:00-10:30am
27	Liu	Jun O.	Discovery of Novel Anticancer Agents from the Johns Hopkins Drug Library	Agents	Biochemical Targets & Drug Screening	Group I: 8:00-10:30am
207	Livingston	David	Papovaviruses as Tools for Cancer Research	Agents	Drug Delivery & Gene Therapy	Group II: 11:00-2:30pm
509	Livneh	Zvi	DNA Repair Enzymes Activity Biomarkers for Risk Assessment and Early Detection of Lung Cancer	Biospecimens	Biomarkers for Lung Cancer Detection & Therapy	Group III: 3:00-5:30pm
80	Lokshin	Anna	Multiplex serum analysis for screening and diagnosis of pancreatic cancer	Biospecimens	-Omic Technology in Biomarker Discovery & Development	Group I: 8:00-10:30am
462	Lokshin	Anna	DEVELOPMENT OF A MULTIMARKER ASSAY FOR EARLY DETECTION OF OVARIAN CANCER	Biospecimens	Biomarkers for Early Detection	Group III: 3:00-5:30pm
295	LoRusso	Patricia	Pivotal Role of Translational Research in the Development of Novel Cancer Treatments by Conduct of Phase I Clinical Trials.	Biospecimens	Prognostic & Predictive Biomarkers	Group II: 11:00-2:30pm
483	Lowe	Anson	The AGR2 gene as a target for early diagnosis and therapeutic intervention	Biospecimens	Biomarkers: Esophagus, Colon, and Liver Cancers	Group III: 3:00-5:30pm
444	Lu	Karen	Enhanced estrogen-induced proliferation and the antagonizing effect of insulin-sensitizing agents Rosiglitazone and Metformin in obese rat endometrium	Agents	Therapeutic Targeting in Pancreatic & Breast Cancer	Group III: 3:00-5:30pm
72	Lucas	David	Silvestrol: A Novel B-cell Selective Agent for Potential Use in Leukemias and Lymphomas	Biospecimens	Biomarkers for Hematologic Malignancies & Pediatric Cancer	Group I: 8:00-10:30am
490	Luketich	James	Molecular Detection of Occult Nodal Metastases in Esophageal Adenocarcinoma.	Biospecimens	Biomarkers: Esophagus, Colon, and Liver Cancers	Group III: 3:00-5:30pm
375	Lutgendorf	Susan	Biobehavioral-Cytokine Interactions in Ovarian Cancer	Lifestyle	Biobehavioral Mechanisms in Cancer Progression & Control	Group II: 11:00-2:30pm
208	Ma	Dangshe	PSMA ADC, an Auristatin-Conjugated Fully Human Monoclonal Antibody to Prostate-Specific Membrane Antigen, for Treatment of Prostate Cancer	Agents	Drug Delivery & Gene Therapy	Group II: 11:00-2:30pm
7	Ma	Haiching	HotSpot ₂ , a Novel Low Cost P33-based Kinase Assay for Kinomic Drug Discovery	Agents	Biochemical Targets & Drug Screening	Group I: 8:00-10:30am
288	Macleod	Kay	Modulation of breast cancer progression by BNIP3	Biospecimens	Biomarkers for Breast Cancer	Group II: 11:00-2:30pm
130	Mahmood	Umar	Molecular Fluorescent Imaging for the Early Detection of Colorectal Neoplasia	Imaging	Imaging Approaches to Cancer Detection	Group I: 8:00-10:30am
39	Maitra	Anirban	An orally bioavailable small molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer	Agents	Cancer Stem Cell, Gene Expression, & Epigenetic Targets	Group I: 8:00-10:30am
484	Makar	Karen	Aspirin, UGT1A6 Genotype and Colon Gene Expression: Results from an Aspirin Intervention Trial	Biospecimens	Biomarkers: Esophagus, Colon, and Liver Cancers	Group III: 3:00-5:30pm
485	Maley	Carlo	Genetic Diversity and Clonal Expansions in the Neoplastic Progression of Barrett's Esophagus	Biospecimens	Biomarkers: Esophagus, Colon, and Liver Cancers	Group III: 3:00-5:30pm
252	Mao	Jenny	Lung Cancer Chemoprevention with Celecoxib in Ex-smokers	Agents	Targeting Head, Neck & Lung Cancers	Group II: 11:00-2:30pm
313	Mao	Li	Genetic Markers for Selecting High-risk Population with Oral Premalignancy for the Erlotinib Prevention of Oral Cancer (EPOC) Trial	Biospecimens	Prognostic & Predictive Biomarkers	Group II: 11:00-2:30pm
463	Martinez-Maza	Otto	Detection of Immune-Related Serologic Biomarkers Prior to Lymphoma Diagnosis	Biospecimens	Biomarkers for Early Detection	Group III: 3:00-5:30pm
511	Massion	Pierre	Validation of patterns of protein expression in preinvasive lung lesions and identification of biomarker signature of lung cancer development	Biospecimens	Biomarkers for Lung Cancer Detection & Therapy	Group III: 3:00-5:30pm
350	Matsui	William	Targeting Cancer Stem Cells (CSC)	IRMs	Cellular Therapy for Immune Response Modification	Group II: 11:00-2:30pm
49	Matsui	William	Targeting Cancer Stem Cells (CSC)	Agents	Cancer Stem Cell, Gene Expression, & Epigenetic Targets	Group I: 8:00-10:30am
312	Mayer	Bruce	SH2 profiling: a sensitive, high-throughput, quantitative method for tumor classification based on phosphotyrosine signaling state	Biospecimens	Prognostic & Predictive Biomarkers	Group II: 11:00-2:30pm
464	McIntosh	Martin	Ovarian Cancer Biomarker Validation Studies Guide New Discovery Strategies	Biospecimens	Biomarkers for Early Detection	Group III: 3:00-5:30pm
486	Mehta	Anand	Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma	Biospecimens	Biomarkers: Esophagus, Colon, and Liver Cancers	Group III: 3:00-5:30pm
479	Meltzer	Stephen J.	A multi-center, double-blinded pre-validation study of methylation biomarkers for progression prediction in Barrett's esophagus	Biospecimens	Biomarkers: Esophagus, Colon, and Liver Cancers	Group III: 3:00-5:30pm
382	Meshinchi	Soheil	Biology and prognostic significance of FLT3 mutations in AML	Agents	Novel Targets in Hematological Malignancies	Group III: 3:00-5:30pm
57	Meshinchi	Soheil	Biology and prognostic significance of FLT3 mutations in AML	Biospecimens	Biomarkers for Hematologic Malignancies & Pediatric Cancer	Group I: 8:00-10:30am
147	Messmer	Bradley	Particle Based MonoClonal Antibody Detection in Serum for Optimal Drug Dosing	IRMs	Antibodies, Cytokines, & Viruses	Group I: 8:00-10:30am
314	Messmer	Bradley	Particle Based MonoClonal Antibody Detection in Serum for Optimal Drug Dosing	Biospecimens	Prognostic & Predictive Biomarkers	Group II: 11:00-2:30pm
436	Miele	Lucio	Rational targeting of Notch signaling in breast cancer	Agents	Therapeutic Targeting in Pancreatic & Breast Cancer	Group III: 3:00-5:30pm
351	Miller	Jeffrey	Exploiting Allogeneic NK Cells in Cancer and Transplantation.	IRMs	Cellular Therapy for Immune Response Modification	Group II: 11:00-2:30pm
507	Minna	John	Molecular Signatures Predicting Response to Therapy in Lung Cancer	Biospecimens	Biomarkers for Lung Cancer Detection & Therapy	Group III: 3:00-5:30pm
131	Misteli	Thomas	Breast Cancer Diagnostics Based On Interphase Spatial Genome Positioning	Imaging	Imaging Approaches to Cancer Detection	Group I: 8:00-10:30am
16	Mitsuya	Hiroaki	Molecular Targeting Approach for Development of Antiviral Therapy of HIV Infectior	Agents	Biochemical Targets & Drug Screening	Group I: 8:00-10:30am

Poster #	Submitter's Last Name	Submitter's First Name	Title	Assigned Pathway	Poster Discussion Session	Concurrent Session
113	Mohler	James	Androgen Dependence of Castration-recurrent Prostate Cancer	Biospecimens	Biomarkers for Prostate & Bladder Cancers	Group I: 8:00-10:30am
50	Molina	Julian	Orthotopic Transplantation of Lung Cancer Stem Cells from Fresh Surgical Specimen as a Clinically Relevant Mouse Models of Non-Small Cell Lung Carcinoma.	Agents	Cancer Stem Cell, Gene Expression, & Epigenetic Targets	Group I: 8:00-10:30am
1	Mor	Gil	ACTIVATION OF CASPASE-INDEPENDENT PROGRAMMED CELL DEATH OVERCOMES APOPTOSIS RESISTANCE IN OVARIAN CANCER CELLS	Agents	Biochemical Targets & Drug Screening	Group I: 8:00-10:30am
291	Mor	Gil	ACTIVATION OF CASPASE-INDEPENDENT PROGRAMMED CELL DEATH OVERCOMES APOPTOSIS RESISTANCE IN OVARIAN CANCER CELLS	Biospecimens	Prognostic & Predictive Biomarkers	Group II: 11:00-2:30pm
209	Morgan	Lee Roy	Clinical Development of 4-Hydroperoxyifosfamide (4-HOOI)	Agents	Drug Delivery & Gene Therapy	Group II: 11:00-2:30pm
210	Morris	John	Novel Radio-Viro Therapy for Prostate Cancer Using the Sodium-Iodide Symporter and 131-I: A Phase I Clinical Trial of Cancer Gene Therapy.	Agents	Drug Delivery & Gene Therapy	Group II: 11:00-2:30pm
168	Nabors	Louis Burt	A Phase I Trial and Molecular Tissue Analysis of Capecitabine Concurrent with Radiation Therapy for Patients Newly Diagnosed with Glioblastoma Multiforme	Devices	Ionizing and Non-Ionizing Radiation	Group I: 8:00-10:30am
199	Napier	Mary	Particle Replication in Non-Wetting Templates (PRINT): Designing Organic Delivery Vehicles for Probing and Treating Biological Systems	Agents	Drug Delivery & Gene Therapy	Group II: 11:00-2:30pm
234	Navone	Nora	FGF SIGNALING AS A TARGET IN PROSTATE CANCER PROGRESSION	Agents	New Agents for the Treatment & Prevention of Prostate Cancer	Group II: 11:00-2:30pm
397	Neckers	Leonard	Hsp90 Dependence of Somatically Mutated Epidermal Growth Factor Receptor and ErbB2	Agents	Novel Targets in Hematological Malignancies	Group III: 3:00-5:30pm
232	Nelson	Pete	Metabolic Adaptation and Intracrine Androgen Synthesis in Metastatic Prostate Cancer: Mechanisms for Castration-Resistant Tumor Growth	Agents	New Agents for the Treatment & Prevention of Prostate Cancer	Group II: 11:00-2:30pm
198	Nelson	Sarah	MR Metabolic and Physiological Imaging as Non-invasive Biomarkers for Evaluation of Patients with Glioma	Agents	Drug Delivery & Gene Therapy	Group II: 11:00-2:30pm
254	Nemenoff	Raphael	Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of PPAR α 947;	Agents	Targeting Head, Neck & Lung Cancers	Group II: 11:00-2:30pm
114	Neuhouser	Marian	Finasteride attenuates the association of elevated C-peptide with increased risk of high grade prostate cancer: The Prostate Cancer Prevention Trial (PCPT).	Biospecimens	Biomarkers for Prostate & Bladder Cancers	Group I: 8:00-10:30am
235	Neuhouser	Marian	Finasteride attenuates the association of elevated C-peptide with increased risk of high grade prostate cancer: The Prostate Cancer Prevention Trial (PCPT).	Agents	New Agents for the Treatment & Prevention of Prostate Cancer	Group II: 11:00-2:30pm
362	Nevo	Erez	MRI-guided breast biopsy system	Devices	Devices for Surgery Ablation and Biopsy	Group II: 11:00-2:30pm
411	Newman	Edward	California Cancer Consortium with Pittsburgh and Penn State: NCI-Supported Infrastructure for Molecular and Clinical Pharmacodynamic Phase I and II Trials	Agents	Integrative Biology: Bench to Bedside	Group III: 3:00-5:30pm
286	Niederhuber	John	Influence of the Wound Microenvironment on Tumor Growth	Biospecimens	Biomarkers for Breast Cancer	Group II: 11:00-2:30pm
78.1	Nolan	Garry P.	Cancer Signaling Subsets and T Cell Immune Responses Stratify Lymphoma Patient Clinical Outcomes	Biospecimens	Biomarkers for Hematologic Malignancies & Pediatric Cancer	Group I: 8:00-10:30am
281	Norton	Larry	Tumor Self-Seeding Links Tumor Growth with Metastasis	Biospecimens	Biomarkers for Breast Cancer	Group II: 11:00-2:30pm
255	Nyati	Mukesh	A Novel Approach to Overcome Cisplatin Resistance by HSP90 Inhibition in Head and Neck Cancer cell lines	Agents	Targeting Head, Neck & Lung Cancers	Group II: 11:00-2:30pm
329	Nyman	Jeffry	Effects of biomechanical properties of bone on the behavior of breast cancer cells resident in bone	Imaging	Imaging and Cancer Therapeutics	Group II: 11:00-2:30pm
433	Nyman	Jeffry	Effects of biomechanical properties of bone on the behavior of breast cancer cells resident in bone	Agents	Therapeutic Targeting in Pancreatic & Breast Cancer	Group III: 3:00-5:30pm
189	Oeffinger	Kevin	Cardiovascular risk and response to a 12-month behaviorally-based Lifestyle intervention among young adult survivors of childhood acute lymphoblastic leukemia	Lifestyle	Dietary Components in Cancer Prevention & Control	Group I: 8:00-10:30am
278	Oesterreich	Steffi	Estrogen and IGF-I crosstalk in breast cancer: Potential therapeutic implications	Biospecimens	Biomarkers for Breast Cancer	Group II: 11:00-2:30pm
394	O'Keefe	Barry	Identification of Inhibitors for MDM2 Ubiquitin Ligase Activity from Natural Products by a Novel High Throughput Electrochemiluminescent Screen.	Agents	Novel Targets in Hematological Malignancies	Group III: 3:00-5:30pm
262.1	Ondrey	Frank	Developmental Pathway for PPAR gamma mediated Chemoprevention of Oral Cancer	Agents	Targeting Head, Neck & Lung Cancers	Group II: 11:00-2:30pm
61	O'Neill	Brian	6q 22-23 as a Biomarker in PCNSL	Biospecimens	Biomarkers for Hematologic Malignancies & Pediatric Cancer	Group I: 8:00-10:30am
125	Oraevsky	Alexander	Hybrid Optoacoustic-Ultrasonic Modality for Diagnostic Imaging of Breast Cancer	Imaging	Imaging Approaches to Cancer Detection	Group I: 8:00-10:30am
339	O'Reilly	Richard	Novel Antigens Differentially Expressed in Pediatric leukemias and solid tumors are promising targets for antibody and cell-based immunotherapies	IRMs	Cellular Therapy for Immune Response Modification	Group II: 11:00-2:30pm
541	O'Reilly	Richard	Epithelial Ovarian Cancer: The Role of MUC16/CA125 (5PO1CA052477-15) Spriggs, D; Livingston, P; O'Reilly R; Sabbatini, P; Barakat, R; Soslow, R and Thaler, H.	IRMs	Cancer Vaccines	Group III: 3:00-5:30pm
489	Orlando	Roy	Mechanisms of Acid Resistance in Barrett's Esophagus	Biospecimens	Biomarkers: Esophagus, Colon, and Liver Cancers	Group III: 3:00-5:30pm
392	Orlowski	Robert	Translation of Proteasome Inhibitor-based Combination Regimens Incorporating Agents That Suppress Mitogen-activated Protein Kinase Pathway Signaling Into the Clinic to Enhance Outcomes of Patients...	Agents	Novel Targets in Hematological Malignancies	Group III: 3:00-5:30pm
437	Osborne	Kent	Targeting the HER Network by Combination drug Therapy to Overcome Resistance in HER2-positive Breast Cancer	Agents	Therapeutic Targeting in Pancreatic & Breast Cancer	Group III: 3:00-5:30pm
169	Oseroff	Allan	Understanding Underlying Mechanisms and Optimizing Photodynamic Therapy (PDT)	Devices	Ionizing and Non-Ionizing Radiation	Group I: 8:00-10:30am
393	Pagel	John	Radiolabeled Antibody Therapy for Treatment of Leukemia and Lymphoma	Agents	Novel Targets in Hematological Malignancies	Group III: 3:00-5:30pm
522	Pai	Sara	Delivery of HPV DNA vaccine via electroporation results in the most potent anti-tumor responses compared to intramuscular injection and gene gun delivery	IRMs	Cancer Vaccines	Group III: 3:00-5:30pm

Poster #	Submitter's Last Name	Submitter's First Name	Title	Assigned Pathway	Poster Discussion Session	Concurrent Session
402	Palanichamy	Kamalakannan	Correlative molecular endpoints from RTOG 0211: Phase I/II study of Gefitinib + radiation for newly diagnosed glioblastoma(GBM)	Agents	Integrative Biology: Bench to Bedside	Group III: 3:00-5:30pm
532	Palucka	Karolina	Dendritic cells as therapeutic vaccines in cancer	IRMs	Cancer Vaccines	Group III: 3:00-5:30pm
533	Pantuck	Allan	A Phase I/II Trial Of Carbonic Anhydrase 9-Molecularly Targeted Kidney Cancer Vaccine Therapy	IRMs	Cancer Vaccines	Group III: 3:00-5:30pm
213	Park	John	Lipidic Nanoparticle-Based Drugs for Brain Tumor Treatment	Agents	Drug Delivery & Gene Therapy	Group II: 11:00-2:30pm
214	Park	John	Novel Liposome and Immunoliposome Drugs Against Aggressive Breast Cancer Subtypes	Agents	Drug Delivery & Gene Therapy	Group II: 11:00-2:30pm
534	Parsa	Andrew	From Benchtop to Bedside: Autologous tumor derived heat shock proteins can evoke a tumor specific immune response in patients with high-grade glioma	IRMs	Cancer Vaccines	Group III: 3:00-5:30pm
466	Pass	Harvey	Mesothelioma Biomarkers: Discovery and Validation	Biospecimens	Biomarkers for Early Detection	Group III: 3:00-5:30pm
283	Patsialou	Antonia	Stromal interaction and migratory pathways identified in invasive tumor cells isolated from human breast tumors	Biospecimens	Biomarkers for Breast Cancer	Group II: 11:00-2:30pm
508	Patz	Ned	Biomarkers for Lung Cancer Metastasis	Biospecimens	Biomarkers for Lung Cancer Detection & Therapy	Group III: 3:00-5:30pm
133	Paulsen	Keith	Imaging the Breast with Alternatives to Conventional Practice	Imaging	Imaging Approaches to Cancer Detection	Group I: 8:00-10:30am
17	Pellechchia	Maurizio	APOPTOSIS-BASED CANCER DRUG DISCOVERY	Agents	Biochemical Targets & Drug Screening	Group I: 8:00-10:30am
18	Penketh	Phil	Development of Anticancer 1,2-Bis(sulfonyl)hydrazines	Agents	Biochemical Targets & Drug Screening	Group I: 8:00-10:30am
377	Petereit	Daniel	Walking Forward: NIH Disparity Project to Lower Cancer Mortality Rates For American Indians in Western, South Dakota	Lifestyle	Biobehavioral Mechanisms in Cancer Progression & Control	Group II: 11:00-2:30pm
449	Petersen	Gloria	Pancreatic cancer-induced diabetes mellitus (DM): Opportunity for risk stratification and early detection	Biospecimens	Biomarkers for Early Detection	Group III: 3:00-5:30pm
236	Pienta	Kenneth	Treating Advanced Cancer by Disrupting the Tumor Ecosystem.	Agents	New Agents for the Treatment & Prevention of Prostate Cancer	Group II: 11:00-2:30pm
190	Pierce	John	Changing diet improved health outcomes among breast cancer survivors without hot flashes and may be explained by circulating estradiol concentrations	Lifestyle	Dietary Components in Cancer Prevention & Control	Group I: 8:00-10:30am
330	Piwnica-Worms	David	Advances in the Science and Education of Molecular Imaging at Washington University	Imaging	Imaging and Cancer Therapeutics	Group II: 11:00-2:30pm
191	Piyathilake	Chandrika	Micronutrient-based approaches for control of high-risk human papillomaviruses and their role in the prevention of cervical Intraepithelial neoplasia	Lifestyle	Dietary Components in Cancer Prevention & Control	Group I: 8:00-10:30am
65	Plevritis	Sylvia	Gene Module Regulatory Network Analysis Reveals Stem-Cell Signature in Follicular Lymphoma Transformation	Biospecimens	Biomarkers for Hematologic Malignancies & Pediatric Cancer	Group I: 8:00-10:30am
510	Podack	Eckhard	Enhanced CD8 CTL cross priming as vaccine principle	Biospecimens	Biomarkers for Lung Cancer Detection & Therapy	Group III: 3:00-5:30pm
535	Podack	Eckhard	Enhanced CD8 CTL cross priming as vaccine principle	IRMs	Cancer Vaccines	Group III: 3:00-5:30pm
20	Pommier	Yves	The Indenoisoquinolines Non-Camptothecin Topoisomerase I Inhibitors: Update and Perspectives	Agents	Biochemical Targets & Drug Screening	Group I: 8:00-10:30am
311	Prystowsky	Michael	Global Proteomic Analysis of HNSCC Identifies Prognostic Markers	Biospecimens	Prognostic & Predictive Biomarkers	Group II: 11:00-2:30pm
74	Puduvalli	Vinay	Ad-sTRAIL, an adenoviral construct expressing soluble TRAIL, improves survival in a bioluminescence imageable intracranial xenograft model and an ex-vivo model of malignant glioma	Biospecimens	Biomarkers for Hematologic Malignancies & Pediatric Cancer	Group I: 8:00-10:30am
215	Puduvalli	Vinay	Ad-sTRAIL, an adenoviral construct expressing soluble TRAIL, improves survival in a bioluminescence imageable intracranial xenograft model and an ex-vivo model of malignant glioma	Agents	Drug Delivery & Gene Therapy	Group II: 11:00-2:30pm
233	Qian	David	Irx5 as a target of prostate cancer therapeutics	Agents	New Agents for the Treatment & Prevention of Prostate Cancer	Group II: 11:00-2:30pm
331	Quinn	Tom	Clinical Translation of Radiolabeled Cancer Imaging and Therapeutic Agents	Imaging	Imaging and Cancer Therapeutics	Group II: 11:00-2:30pm
315	Ratain	Mark	Early Clinical Trials Focused on Biomarkers	Biospecimens	Prognostic & Predictive Biomarkers	Group II: 11:00-2:30pm
413	Ratain	Mark	Early Clinical Trials Focused on Biomarkers	Agents	Integrative Biology: Bench to Bedside	Group III: 3:00-5:30pm
148	Raubitschek	Andrew	A Phase I Study of De-Immunized DI-Leu16-IL2 Immunocytokine in Patients with B-cell Non-Hodgkin's Lymphoma	IRMs	Antibodies, Cytokines, & Viruses	Group I: 8:00-10:30am
73	Reaman	Gregory	Biomarkers for risk and target identifications in pediatric AML	Biospecimens	Biomarkers for Hematologic Malignancies & Pediatric Cancer	Group I: 8:00-10:30am
476	Reid	Brian	NSAIDs Modulate CDKN2A, TP53, and DNA Content Risk for Progression to Esophageal Adenocarcinoma (EA)	Biospecimens	Biomarkers: Esophagus, Colon, and Liver Cancers	Group III: 3:00-5:30pm
256	Reid	Mary	Premalignant Lesions of the Lung and Calcitriol: A Phase II Study	Agents	Targeting Head, Neck & Lung Cancers	Group II: 11:00-2:30pm
134	Reiter	Robert	Translation of Radiolabelled Prostate Stem Cell Antigen (PSCA) Antibody Fragments to the Clinic	Imaging	Imaging Approaches to Cancer Detection	Group I: 8:00-10:30am
160	Repasky	Elizabeth	Improving the Efficacy of Cancer Therapies by Defining and Exploiting Thermally Sensitive Vascular and Immunological Targets	Devices	Ionizing and Non-Ionizing Radiation	Group I: 8:00-10:30am
285	Richardson	Andrea	Identification of Predictors of Response in a Phase II trial of Preoperative Cis-platinum in Early Stage Triple-Negative Breast Cancer	Biospecimens	Biomarkers for Breast Cancer	Group II: 11:00-2:30pm
414	Richardson	Andrea	Identification of Predictors of Response in a Phase II trial of Preoperative Cis-platinum in Early Stage Triple-Negative Breast Cancer	Agents	Integrative Biology: Bench to Bedside	Group III: 3:00-5:30pm
491	Ried	Thomas	Exploiting the genome and transcriptome for individualized cancer diagnosis and treatment stratification	Biospecimens	Biomarkers: Esophagus, Colon, and Liver Cancers	Group III: 3:00-5:30pm
378	Robbins	Mike	Blockade of the Renin-angiotensin System leads to Prevention or Amelioration of Radiation-induced Cognitive Impairment	Lifestyle	Biobehavioral Mechanisms in Cancer Progression & Control	Group II: 11:00-2:30pm
536	Robert-Guroff	Marjorie	Replicating Adenovirus-HIV Recombinants Provide a Comprehensive Vaccine Approach	IRMs	Cancer Vaccines	Group III: 3:00-5:30pm
537	Roden	Richard	Polymeric L2 as an inexpensive and broadly protective Human papillomavirus vaccine	IRMs	Cancer Vaccines	Group III: 3:00-5:30pm

Poster #	Submitter's Last Name	Submitter's First Name	Title	Assigned Pathway	Poster Discussion Session	Concurrent Session
456	Rodriguez	Gus	Ovarian Adenocarcinomas in the Laying Hen and Women Share Similar Alterations in p53, ras, & HER-2/neu	Biospecimens	Biomarkers for Early Detection	Group III: 3:00-5:30pm
512	Rom	William	Reactivity to Tumor Associated Antigens in the Evaluation of Pulmonary Nodules	Biospecimens	Biomarkers for Lung Cancer Detection & Therapy	Group III: 3:00-5:30pm
488	Rosenberg	Daniel	Using proteomics to develop chemoprevention targets for colon cancer	Biospecimens	Biomarkers: Esophagus, Colon, and Liver Cancers	Group III: 3:00-5:30pm
21	Rosenfeld	Michael	Receptors and Transformation	Agents	Biochemical Targets & Drug Screening	Group I: 8:00-10:30am
513	Roth	Jack	Systemic Therapy with Tumor Suppressor FUS1-nanoparticles for Stage IV Lung Cancer	Biospecimens	Biomarkers for Lung Cancer Detection & Therapy	Group III: 3:00-5:30pm
415	Roth	Michael	Creating an Academic Drug Discovery Environment	Agents	Integrative Biology: Bench to Bedside	Group III: 3:00-5:30pm
120	Rowley	David	Biomarkers and Targeting the Reactive Stroma Microenvironment in Prostate Cancer Progression	Biospecimens	Biomarkers for Prostate & Bladder Cancers	Group I: 8:00-10:30am
135	Roy	Hemant	Rectal Optical Signatures as a Marker for Colonic Field Carcinogenesis: Applications for Minimally Invasive Mechanism for Risk Stratification	Imaging	Imaging Approaches to Cancer Detection	Group I: 8:00-10:30am
379	Rubin	Jeffrey	Palifermin Reduces the Incidence of Chemoradiotherapy-Induced Severe Oral Mucositis in Patients with Head and Neck Cancer	Lifestyle	Biobehavioral Mechanisms in Cancer Progression & Control	Group II: 11:00-2:30pm
52	Ruppert	J. Michael	KLF4 regulates Notch1 transcription and signaling during epithelial transformation	Agents	Cancer Stem Cell, Gene Expression, & Epigenetic Targets	Group I: 8:00-10:30am
487	Rustgi	Anil	The interplay of transformed epithelial cells and stromal fibroblasts in the tumor microenvironment	Biospecimens	Biomarkers: Esophagus, Colon, and Liver Cancers	Group III: 3:00-5:30pm
192	Ryan	Elizabeth	Identification of Selenium Responders: Who Will Benefit from Selenium Supplementation for Cancer Risk Reduction?	Lifestyle	Dietary Components in Cancer Prevention & Control	Group I: 8:00-10:30am
149	Salazar	Lupe	Phase I Study of Intraperitoneal Denileukin Diftitox (ONTAK) in Patients with Advanced Ovarian Cancer.	IRMs	Antibodies, Cytokines, & Viruses	Group I: 8:00-10:30am
247	Salgia	Ravi	Role of MET Receptor Tyrosine Kinase in Small Cell Lung Cancer and Potential for Novel Therapy	Agents	Targeting Head, Neck & Lung Cancers	Group II: 11:00-2:30pm
538	Sampson	John	EGFRvIII-targeted Vaccine (CDX-110) induces immune responses and prolongs TTP when given with simultaneous standard and continuous temozolomide in patients with GBM	IRMs	Cancer Vaccines	Group III: 3:00-5:30pm
112	Sanda	Martin	Identifying Multiplex Expressed Gene Targets for Prostate Cancer Detection and Establishing a Prospective, Multi-center Case-Control Repository for their Validation at the Harvard-Michigan EDNR-CEVC	Biospecimens	Biomarkers for Prostate & Bladder Cancers	Group I: 8:00-10:30am
217	Sandmaier	Brenda	Astatine-211 Conditioning for Nonmyeloablative Hematopoietic Stem Cell Allografts	Agents	Drug Delivery & Gene Therapy	Group II: 11:00-2:30pm
136	Sarvazyen	Armen	Tactile Imaging of the Breast: Cancer Screening and Diagnostic Potential	Imaging	Imaging Approaches to Cancer Detection	Group I: 8:00-10:30am
380	Saykin	Andrew	Mechanisms of Chemotherapy-Induced Cognitive Changes: Prospective Structural, Functional and Diffusion Tensor Brain MRI in Breast Cancer Patients	Lifestyle	Biobehavioral Mechanisms in Cancer Progression & Control	Group II: 11:00-2:30pm
116	Scher	Howard	MDV3100, A Novel Androgen Receptor Antagonist for Castration Resistant Prostate Cancer (CRPC)	Biospecimens	Biomarkers for Prostate & Bladder Cancers	Group I: 8:00-10:30am
237	Scher	Howard	MDV3100, A Novel Androgen Receptor Antagonist for Castration Resistant Prostate Cancer (CRPC)	Agents	New Agents for the Treatment & Prevention of Prostate Cancer	Group II: 11:00-2:30pm
539	Schiller	John	Development and Assessment of Interventions to Prevent Oncogenic HPV Infection	IRMs	Cancer Vaccines	Group III: 3:00-5:30pm
316	Schilsky	Richard	Translational Research by the Cancer and Leukemia Group B	Biospecimens	Prognostic & Predictive Biomarkers	Group II: 11:00-2:30pm
96	Schnitzer	Jan	Proteomic mapping of endothelial caveolae to pump radio-antibodies into tumors for specific imaging and therapy	Biospecimens	-Omic Technology in Biomarker Discovery & Development	Group I: 8:00-10:30am
211	Schnitzer	Jan	Proteomic mapping of endothelial caveolae to pump radio-antibodies into tumors for specific imaging and therapy	Agents	Drug Delivery & Gene Therapy	Group II: 11:00-2:30pm
71	Scully	Becca	Frequency of Mitochondrial DNA and Hemochromatosis Gene Mutations in Survivors of Pediatric Acute Lymphoblastic Leukemia at Risk for Anthracycline-Cardiotoxicity	Biospecimens	Biomarkers for Hematologic Malignancies & Pediatric Cancer	Group I: 8:00-10:30am
22	Sebti	Said	Targeting geranylgeranyltransferase I for anti-cancer drug therapy in tumors with hyper-activated Ras / Ral GDS / Ral A/B and/or with low p27Kip	Agents	Biochemical Targets & Drug Screening	Group I: 8:00-10:30am
23	Sebti	Said	Targeting signal transduction pathways for cancer drug discovery	Agents	Biochemical Targets & Drug Screening	Group I: 8:00-10:30am
24	Sebti	Said	Developing Withacnistin as a novel anti-cancer drugs in tumors that contain persistently activated STAT3	Agents	Biochemical Targets & Drug Screening	Group I: 8:00-10:30am
352	Seeger	Robert	Biology and Therapy of High-Risk Neuroblastoma	IRMs	Cellular Therapy for Immune Response Modification	Group II: 11:00-2:30pm
76	Seeger	Robert	Biology and Therapy of High-Risk Neuroblastoma	Biospecimens	Biomarkers for Hematologic Malignancies & Pediatric Cancer	Group I: 8:00-10:30am
92	Seewaldt	Victoria	Prospective Identification of Reverse Phase Proteomic Signatures of Estrogen Resistance in High-Risk Premenopausal Women	Biospecimens	-Omic Technology in Biomarker Discovery & Development	Group I: 8:00-10:30am
54	Seiden	Michael	Targeting Signaling Networks via RNAi Approaches to Improve the Treatment of Patients with Ovarian Cancer	Agents	Cancer Stem Cell, Gene Expression, & Epigenetic Targets	Group I: 8:00-10:30am
260	Seiwert	Tanguy	DNA Damage Targeted Gene Therapy in Head and Neck Cancer	Agents	Targeting Head, Neck & Lung Cancers	Group II: 11:00-2:30pm
117	Semmes	John	The Application of Imaging Mass Spectrometry in the Development of Biomarkers for Improved Clinical Decision Making in Prostate Cancer	Biospecimens	Biomarkers for Prostate & Bladder Cancers	Group I: 8:00-10:30am
317	Sgroi	Dennis	Comparison of Risk Stratification by the Combined HOXB13/IL17BR and Molecular Grade Indices Versus OncotypeDX in Early Stage ER+ Breast Cancer Patients from Multiple Institutions.	Biospecimens	Prognostic & Predictive Biomarkers	Group II: 11:00-2:30pm
333	Shah	Manish	Early FDG-PET/CT predicts patient outcome to preoperative irinotecan and cisplatin: results of a phase II therapeutic study for locally advanced gastric cancer	Imaging	Imaging and Cancer Therapeutics	Group II: 11:00-2:30pm
416	Shannon	Kevin	The Use of Genetically Engineered Mice to Investigate Treatment Response and Resistance	Agents	Integrative Biology: Bench to Bedside	Group III: 3:00-5:30pm
25	Shapiro	Geoffrey	Pharmacodynamic Assessments of Cyclin-Dependent Kinase Inhibitors: Modulation of Cdk Targets in Clinical Samples	Agents	Biochemical Targets & Drug Screening	Group I: 8:00-10:30am
438	Sharkey	Bob	Bispecific antibody pretargeted radioimmunodetection and therapy of pancreatic cancer.	Agents	Therapeutic Targeting in Pancreatic & Breast Cancer	Group III: 3:00-5:30pm

Poster #	Submitter's Last Name	Submitter's First Name	Title	Assigned Pathway	Poster Discussion Session	Concurrent Session
385	Shaughnessy	John	Total Therapy (TT) for Myeloma (MM): 10% Cure Rate	Agents	Novel Targets in Hematological Malignancies	Group III: 3:00-5:30pm
26	Shen	Ben	Natural product-based anticancer drug discovery: the National Cooperative Drug Discovery Group at University of Wisconsin-Madison	Agents	Biochemical Targets & Drug Screening	Group I: 8:00-10:30am
241	Shin	Dong	Role of Akt-Foxo1a Signaling in Synergistic Growth Inhibition of Squamous Cell Carcinoma of the Head and Neck by EGFR Tyrosine Kinase Inhibitor Erlotinib and Green Tea Polyphenol EGCG	Agents	Targeting Head, Neck & Lung Cancers	Group II: 11:00-2:30pm
75	Showe	Louise	Development and Validation of a highly accurate classifier for CTCL using microarrays and Q-RT-PCR	Biospecimens	Biomarkers for Hematologic Malignancies & Pediatric Cancer	Group I: 8:00-10:30am
474	Shureiqi	Imad	Celecoxib Modulation of Lipoxygenase Pathways in Colonic Mucosa of FAP Patients	Biospecimens	Biomarkers: Esophagus, Colon, and Liver Cancers	Group III: 3:00-5:30pm
258	Siegfried	Jill	Role of estrogens and estrogen receptors in growth and progression of non-small cell lung cancer	Agents	Targeting Head, Neck & Lung Cancers	Group II: 11:00-2:30pm
28	Singer	Sam	Targeting Cell Cycle and Checkpoint Pathways in Well-differentiated and Dedifferentiated Liposarcoma	Agents	Biochemical Targets & Drug Screening	Group I: 8:00-10:30am
441	Singh	Shivendra	Chemopreventive and Therapeutic Effects of Cruciferous Vegetable Constituent Benzyl Isothiocyanate Against Breast Cancer	Agents	Therapeutic Targeting in Pancreatic & Breast Cancer	Group III: 3:00-5:30pm
495	Sirica	Alphonse	A Novel Rat "Patient-Like" Model of Intrahepatic	Biospecimens	Biomarkers: Esophagus, Colon, and Liver Cancers	Group III: 3:00-5:30pm
419	Siu	Lillian	Translational Research Program for Novel First-in-Human Cancer Drugs	Agents	Integrative Biology: Bench to Bedside	Group III: 3:00-5:30pm
271	Smith	Jeffery	Effect of protein phosphatase 2A subunit gene haplotypes and proliferative breast disease on breast cancer risk	Biospecimens	Biomarkers for Breast Cancer	Group II: 11:00-2:30pm
99	Smith	Richard D.	A new Platform of much Higher throughput Proteomics for Biomarker Discovery and Validation	Biospecimens	-Omic Technology in Biomarker Discovery & Development	Group I: 8:00-10:30am
105	Smith	Steve	EPS Markers in the Early Detection of Prostate Cancer	Biospecimens	Biomarkers for Prostate & Bladder Cancers	Group I: 8:00-10:30am
374	Sood	Anil	Neuroendocrine modulation of STAT3 in ovarian cancer	Lifestyle	Biobehavioral Mechanisms in Cancer Progression & Control	Group II: 11:00-2:30pm
48	Sood	Anil	Alterations In Endothelial Cell Gene Expression In Human Ovarian Cancer	Agents	Cancer Stem Cell, Gene Expression, & Epigenetic Targets	Group I: 8:00-10:30am
540	Spaulding	David	GMP-Grade KLH Carrier Protein for Therapeutic Vaccines	IRMs	Cancer Vaccines	Group III: 3:00-5:30pm
373	Spiegel	David	Stress-Related Regional Brain Activation During A Verbal Declarative Memory Task In Metastatic Breast Cancer	Lifestyle	Biobehavioral Mechanisms in Cancer Progression & Control	Group II: 11:00-2:30pm
170	Stabin	Michael	Realistic Phantoms for Clinical and Preclinical Dose Calculations	Devices	Ionizing and Non-Ionizing Radiation	Group I: 8:00-10:30am
165	Stadler	Walter	Radiation-Induced TNF-alpha Therapy in Prostate Cancer	Devices	Ionizing and Non-Ionizing Radiation	Group I: 8:00-10:30am
205	Stadler	Walter	Radiation-Induced TNF-alpha Therapy in Prostate Cancer	Agents	Drug Delivery & Gene Therapy	Group II: 11:00-2:30pm
188	Stark	Jennifer	Obesity and Prostate Cancer Progression in the Physicians' Health Study	Lifestyle	Dietary Components in Cancer Prevention & Control	Group I: 8:00-10:30am
457	Stass	Sandy	Demonstration of Performance Qualification of the Microsatellite Marker Assay for Detection of Bladder Cancer	Biospecimens	Biomarkers for Early Detection	Group III: 3:00-5:30pm
435	Stegg	Patricia	Studies directed toward the prevention and treatment of brain metastasis from breast cancer	Agents	Therapeutic Targeting in Pancreatic & Breast Cancer	Group III: 3:00-5:30pm
363	Stefansic	Jim	Clinical Utility of Image-Guided Liver Surgery	Devices	Devices for Surgery Ablation and Biopsy	Group II: 11:00-2:30pm
55	Stein	Gary S.	Nuclear Structure and Cancer	Agents	Cancer Stem Cell, Gene Expression, & Epigenetic Targets	Group I: 8:00-10:30am
274	Sukumar	Sara	Hypermethylated gene markers-pilot studies testing their utility in risk assessment and as biomarkers of cancer in women with spontaneous nipple discharge	Biospecimens	Biomarkers for Breast Cancer	Group II: 11:00-2:30pm
150	Sullivan	Dan	Overcoming Tumor Antigen Anergy in Human Malignancies Using the Novel IDO Enzyme Inhibitor, 1-Methyl-D-Tryptophan	IRMs	Antibodies, Cytokines, & Viruses	Group I: 8:00-10:30am
41	Sznol	Mario	DNA methylation, gene expression and genetic background as markers for advanced melanoma and responsiveness to 5-Aza-2 ζ -Deoxy-Cytidine induced growth arrest	Agents	Cancer Stem Cell, Gene Expression, & Epigenetic Targets	Group I: 8:00-10:30am
303	Sznol	Mario	DNA methylation, gene expression and genetic background as markers for advanced melanoma and responsiveness to 5-Aza-2 ζ -Deoxy-Cytidine induced growth arrest	Biospecimens	Prognostic & Predictive Biomarkers	Group II: 11:00-2:30pm
460	Takacs	Laszlo	Discovery and Validation of Lung Cancer Specific Monoclonal Antibodies	Biospecimens	Biomarkers for Early Detection	Group III: 3:00-5:30pm
77	Taylor	Kristen	DNA Methylation as Biomarkers in Non-Hodgkin's Lymphoma	Biospecimens	Biomarkers for Hematologic Malignancies & Pediatric Cancer	Group I: 8:00-10:30am
429	Tepper	Joel	Pancreatic Cancer Radiosensitization by Nelfinavir.	Agents	Therapeutic Targeting in Pancreatic & Breast Cancer	Group III: 3:00-5:30pm
118	Theodorescu	Dan	Signaling and Progression in Prostate Cancer	Biospecimens	Biomarkers for Prostate & Bladder Cancers	Group I: 8:00-10:30am
15	Thiele-Galetto	Carol	Development of an in vivo model to study the role of TrkB in tumor biology and to develop novel therapies targeting activated TrkB	Agents	Biochemical Targets & Drug Screening	Group I: 8:00-10:30am
194	Thompson	Henry	Coupling Dieting for Weight Loss and Chemoprevention: Can Intermediary Metabolism Be Targeted to Use Cancer's Achilles Heel for Prevention That Is Sustained in the Absence of Continuous Treatment?	Lifestyle	Dietary Components in Cancer Prevention & Control	Group I: 8:00-10:30am
101	Thompson	Ian	Risk Assessment for Prostate Cancer Detection	Biospecimens	Biomarkers for Prostate & Bladder Cancers	Group I: 8:00-10:30am
238	Thompson	Tim	GLIPR1: a novel tumor suppressor protein with therapeutic potential	Agents	New Agents for the Treatment & Prevention of Prostate Cancer	Group II: 11:00-2:30pm
287	Thorner	Aaron	Analysis of B-Myb in Basal-like Breast Cancer	Biospecimens	Biomarkers for Breast Cancer	Group II: 11:00-2:30pm

Poster #	Submitter's Last Name	Submitter's First Name	Title	Assigned Pathway	Poster Discussion Session	Concurrent Session
110	Tindall	Donald	A Tissue Biomarker Panel Predicting Systemic Progression after PSA Recurrence Post-definitive Prostate Cancer Therapy	Biospecimens	Biomarkers for Prostate & Bladder Cancers	Group I: 8:00-10:30am
276	Tlsty	Thea	Biomarkers to Predict Subsequent Tumor Events in Women Diagnosed with DCIS	Biospecimens	Biomarkers for Breast Cancer	Group II: 11:00-2:30pm
418	Tlsty	Thea	Using Theranostic Targets for the Identification and Elimination of Non-Invasive Basal-like Breast Carcinomas in Young Women	Agents	Integrative Biology: Bench to Bedside	Group III: 3:00-5:30pm
395	Tricot	Guido	Gene Expression Profiling (GEP) versus Quality of Response Assessment in Myelom	Agents	Novel Targets in Hematological Malignancies	Group III: 3:00-5:30pm
542	Trimble	Connie	Immune Therapies for HPV disease: Lessons learned from Phase I	IRMs	Cancer Vaccines	Group III: 3:00-5:30pm
259	Unger	Beth	Biorepository for Validation of Biomarkers for Cervical Cancer Screening: Incorporation of Virtual Slide Repository for Improved Endpoint Determination	Agents	Targeting Head, Neck & Lung Cancers	Group II: 11:00-2:30pm
469	Urban	Nicole	HE4 has strong translational potential as an early detection marker for ovarian cancer	Biospecimens	Biomarkers for Early Detection	Group III: 3:00-5:30pm
440	Usary	Jerry	Therapeutic Sensitivities of Transgenic Mouse Models of Human Breast Cancer	Agents	Therapeutic Targeting in Pancreatic & Breast Cancer	Group III: 3:00-5:30pm
219	Vallera	Daniel	Systemic orthotopic, anti-pancreatic cancer effects in vivo with a novel bispecific ligand-directed toxin delivered using a new method of drug delivery	Agents	Drug Delivery & Gene Therapy	Group II: 11:00-2:30pm
503	Varella-Garcia	Marileila	CO-AMPLIFICATION OF MYC AND EIF3H SIGNIFICANTLY IMPROVE RESPONSE AND SURVIVAL IN NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH GEFITINII	Biospecimens	Biomarkers for Lung Cancer Detection & Therapy	Group III: 3:00-5:30pm
37	Villalona	Miguel	Targeting Epigenetic Modifications in Breast Cancer	Agents	Cancer Stem Cell, Gene Expression, & Epigenetic Targets	Group I: 8:00-10:30am
496	Waldman	Scott	GUCY2C in Lymph Nodes Predicts Time to Recurrence and Disease-Free Survival in pN0 Colorectal Cancer	Biospecimens	Biomarkers: Esophagus, Colon, and Liver Cancers	Group III: 3:00-5:30pm
152	Waldmann	Thomas	IL-15 in the Treatment of Metastatic Malignant Melanoma or Metastatic Renal Cell Carcinoma	IRMs	Antibodies, Cytokines, & Viruses	Group I: 8:00-10:30am
376	Walter	Jeanne	PNI-BASED STRESS MANAGEMENT IN EARLY BREAST CANCER	Lifestyle	Biobehavioral Mechanisms in Cancer Progression & Control	Group II: 11:00-2:30pm
364	Wang	Kenneth	Endoscopic Therapy of Early Adenocarcinoma in Barrett's Esophagus	Devices	Devices for Surgery Ablation and Biopsy	Group II: 11:00-2:30pm
318	Wang	Shan	Rapid and Multiplex Molecular Diagnosis and Therapeutic Monitoring of Cancer Based on Real-Time Magnetic Nanotag Sensing	Biospecimens	Prognostic & Predictive Biomarkers	Group II: 11:00-2:30pm
29	Wang	Shaomeng	Discovery and development of novel small-molecule inhibitors of Bcl-2 and Bcl-xL proteins as a new class of anticancer drugs	Agents	Biochemical Targets & Drug Screening	Group I: 8:00-10:30am
492	Wang	Xin	Array-based Comparative Genomic Hybridization reveals potential tumor driver genes in hepatocellular carcinoma with stem/progenitor cell-like phenotype	Biospecimens	Biomarkers: Esophagus, Colon, and Liver Cancers	Group III: 3:00-5:30pm
240	Wang	Zhou	5a-reductase inhibition in intermittent ADT	Agents	New Agents for the Treatment & Prevention of Prostate Cancer	Group II: 11:00-2:30pm
154	Weiner	George	Initial Rituximab Infusion Induces Rapid NK Activation that Persists after Resolution of Infusion Reactions	IRMs	Antibodies, Cytokines, & Viruses	Group I: 8:00-10:30am
155.1	Weiner	Louis M.	Improving the Efficacy of Unconjugated Monoclonal Antibody Therapy	IRMs	Antibodies, Cytokines, & Viruses	Group I: 8:00-10:30am
544	Weiss	Jonathan	IL-2-Based Combination Immunotherapy Coordinates Innate and Adaptive Immune Responses for the Improved Treatment of Mouse and Human Renal Cell Carcinoma	IRMs	Cancer Vaccines	Group III: 3:00-5:30pm
137	Weissfeld	Joel	The Pittsburgh Lung Screening Study (PLuSS): A Research Cohort of Current and Former Cigarette Smokers Screened for Lung Cancer with Helical Computerized Tomography (CT)	Imaging	Imaging Approaches to Cancer Detection	Group I: 8:00-10:30am
420	Whang	Edward	CEACAM6: A Promising Biomarker and Therapeutic Target for Pancreatic Adenocarcinoma	Agents	Therapeutic Targeting in Pancreatic & Breast Cancer	Group III: 3:00-5:30pm
216	Whitley	Richard	Successful Oncology Translational Research: The UAB-University of Chicago Experience with Engineered HSV for Glioma Therapy Program Project Grant (PPG)	Agents	Drug Delivery & Gene Therapy	Group II: 11:00-2:30pm
516	Wiley	Jim	Lung Cancer Diagnostic Test Validation in Transthoracic Fine Needle Aspirate Specimens	Biospecimens	Biomarkers for Lung Cancer Detection & Therapy	Group III: 3:00-5:30pm
172	Williamson	Jeffrey	Uncertainty-informed image-guided adaptive radiation therapy: towards optimal decision making from imperfect data	Devices	Ionizing and Non-Ionizing Radiation	Group I: 8:00-10:30am
78	Willman	Cheryl	Gene Expression Classifiers for Minimal Residual Disease (MRD) and Relapse Free Survival (RFS) Improve Outcome Prediction and Risk Classification in Children with High Risk Acute Leukemia	Biospecimens	Biomarkers for Hematologic Malignancies & Pediatric Cancer	Group I: 8:00-10:30am
261	Wink	Dave	Evaluation of Redox based Non Steroidal Anti-inflammatory Drugs in Models of Cancer Treatment.	Agents	Targeting Head, Neck & Lung Cancers	Group II: 11:00-2:30pm
517	Wistuba	Ignacio	Molecular Classification of Non-Small Cell Lung Cancer (NSCLC) for Prognosis and Response to Treatment Prediction	Biospecimens	Biomarkers for Lung Cancer Detection & Therapy	Group III: 3:00-5:30pm
545	Wolchok	Jedd	Clinical Development of DNA Vaccines for Melanoma	IRMs	Cancer Vaccines	Group III: 3:00-5:30pm
309	Wolf	Gregory	Biomarkers to predict response to organ sparing therapy in oropharynx cancer	Biospecimens	Prognostic & Predictive Biomarkers	Group II: 11:00-2:30pm
282	Wolmark	Norman	NSABP Biospecimen Bank	Biospecimens	Biomarkers for Breast Cancer	Group II: 11:00-2:30pm
412	Wolmark	Norman	NSABP Biospecimen Bank	Agents	Integrative Biology: Bench to Bedside	Group III: 3:00-5:30pm
173	Wong	John	An Image Guided Small Animal Radiation Platform for Preclinical Research	Devices	Ionizing and Non-Ionizing Radiation	Group I: 8:00-10:30am
546	Wood	Lauren	Proposal for a Phase I/II Clinical Trial of a Therapeutic HER-2/neu Expressing Adenoviral Vector Dendritic Cell Vaccine that Cures Large Established Breast Cancers and Lung Metastases in Mice	IRMs	Cancer Vaccines	Group III: 3:00-5:30pm
223	Wu	Lily	Suppression of Prostate Cancer Nodal and Systemic Metastasis by Blockade of the Lymphangiogenic Axis	Agents	New Agents for the Treatment & Prevention of Prostate Cancer	Group II: 11:00-2:30pm
155	Wu	T.C.	Pretreatment with cisplatin enhances antigen-specific CD8+ T cell-mediated antitumor immunity induced by therapeutic DNA vaccination	IRMs	Antibodies, Cytokines, & Viruses	Group I: 8:00-10:30am

Poster #	Submitter's Last Name	Submitter's First Name	Title	Assigned Pathway	Poster Discussion Session	Concurrent Session
121	Wu	Xifeng	Large Scale Evaluation of Candidate Genes Identifies Novel Low-penetrance Bladder Cancer Susceptibility Loci	Biospecimens	Biomarkers for Prostate & Bladder Cancers	Group I: 8:00-10:30am
471	Xing	Mingzhao	Genetic and Epigenetic Events in Papillary Thyroid Cancer and Their Potential for Clinical Translation	Biospecimens	Biomarkers for Early Detection	Group III: 3:00-5:30pm
51	Yarchoan	Robert	Targeted Therapy of Kaposi's Sarcoma-Associated Herpesvirus (KSHV)-Associated Multicentric Castleman's Disease (MCD) Using Antiviral Drugs that are Activated to Toxic Moieties by KSHV Lytic Genes	Agents	Cancer Stem Cell, Gene Expression, & Epigenetic Targets	Group I: 8:00-10:30am
85	Yeaman	Timothy	Molecular Fingerprints of Cancer in Histologically-Normal Breast Tissues	Biospecimens	-Omic Technology in Biomarker Discovery & Development	Group I: 8:00-10:30am
122	Yegnasubramanian	Vasan	DNA methylation changes in prostate cancer: promise as biomarkers of diagnosis and risk stratification	Biospecimens	Biomarkers for Prostate & Bladder Cancers	Group I: 8:00-10:30am
442	Yeh	Jen Jen	Identification of RalB as a therapeutic target for metastatic pancreatic cancer.	Agents	Therapeutic Targeting in Pancreatic & Breast Cancer	Group III: 3:00-5:30pm
31	Yoon	Sam	A phase II study of neoadjuvant bevacizumab and radiation therapy for resectable soft tissue sarcomas	Agents	Biochemical Targets & Drug Screening	Group I: 8:00-10:30am
195	Young	Matthew	Discovery and validation of molecular targets, biomarkers and non-toxic interventions for cancer prevention.	Lifestyle	Dietary Components in Cancer Prevention & Control	Group I: 8:00-10:30am
443	Young	Matthew	Discovery and validation of molecular targets, biomarkers and non-toxic interventions for cancer prevention.	Agents	Therapeutic Targeting in Pancreatic & Breast Cancer	Group III: 3:00-5:30pm
365	Yu	Cedric	Image Guided Stereotactic Radiosurgery of Breast Cancer	Devices	Devices for Surgery Ablation and Biopsy	Group II: 11:00-2:30pm
280	Yu	Dihua	14-3-3zeta in the Early Stages of Breast Cancer Progression: Luminal Filling and Epithelial Mesenchymal Transition	Biospecimens	Biomarkers for Breast Cancer	Group II: 11:00-2:30pm
12	Yung	Alfred	Cellular and in vivo activity of a new PI3K inhibitor-PX866 for treatment of human glioblastoma	Agents	Biochemical Targets & Drug Screening	Group I: 8:00-10:30am
326	Yung	Alfred	Cellular and in vivo activity of a new PI3K inhibitor-PX866 for treatment of human glioblastoma	Imaging	Imaging and Cancer Therapeutics	Group II: 11:00-2:30pm
100	Zangar	Rick	Discovery and Validation of Cancer Biomarkers Using Integrated Technology Platforms	Biospecimens	-Omic Technology in Biomarker Discovery & Development	Group I: 8:00-10:30am
138	Zavislan	Jim	Multi-Wavelength Confocal Imaging for Skin Lesions	Imaging	Imaging Approaches to Cancer Detection	Group I: 8:00-10:30am
97	Zeiger	Martha	Molecular Classification of Suspicious Thyroid Tumors	Biospecimens	-Omic Technology in Biomarker Discovery & Development	Group I: 8:00-10:30am
319	Zhou	Tong	DDX3 Associates with DR5 and Negatively Regulates Apoptosis Signal Transduction of the Death Domain	Biospecimens	Prognostic & Predictive Biomarkers	Group II: 11:00-2:30pm
32	Zhou	Tong	DDX3 Associates with DR5 and Negatively Regulates Apoptosis Signal Transduction of the Death Domain	Agents	Biochemical Targets & Drug Screening	Group I: 8:00-10:30am